

Q3 2022 REPORT



A VITAL LINK
IN HEALTHCARE



ANDLAUER HEALTHCARE GROUP INC.

**Management's Discussion and Analysis
of Financial Condition and Results of Operations
for the three and nine-month periods ended September 30, 2022 and 2021**

November 8, 2022

TABLE OF CONTENTS

Cautionary Note Regarding Forward-Looking Information	3
Basis of Presentation	5
Non-IFRS Measures	5
Overview.....	6
Summary of Factors Affecting Performance	7
How We Assess the Performance of Our Business	11
Selected Consolidated Financial Information.....	14
Reconciliation of Non-IFRS Measures.....	16
Results of Operations	16
Summary of Quarterly Results	24
Liquidity & Capital Resources.....	25
Cash Flows	28
Contractual Obligations.....	29
Off-Balance Sheet Arrangements	30
Seasonality.....	30
Financial Instruments	30
Related Party Transactions.....	31
Critical Accounting Judgements and Estimates	34
Significant New Accounting Standards	35
Accounting Classifications and Fair Values	35
Risk Factors.....	35
Outstanding Share Data.....	37
Disclosure Controls and Procedures and Internal Controls Over Financial Reporting	37
Additional Information	39

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three and nine-month periods ended September 30, 2022 and 2021 should be read in conjunction with Andlauer Healthcare Group Inc.’s unaudited interim condensed consolidated financial statements for the three and nine-month periods ended September 30, 2022 and 2021, along with the related notes thereto and the audited annual consolidated financial statements, related notes thereto and MD&A for the years ended December 31, 2021 and 2020. This MD&A is presented as of November 8, 2022 and is current to that date unless otherwise stated.

All references in this MD&A to the “Company”, “AHG”, “us”, “our” or “we” refer to Andlauer Healthcare Group Inc., together with our direct and indirect subsidiaries, on a consolidated basis, which is referred to as “the Company” in our financial statements. Additionally, all references to “Q3 2022” are to the three months ended September 30, 2022; “Q3 2021” are to the three months ended September 30, 2021; “Q2 2022” are to the three months ended June 30, 2022; “Q2 2021” are to the three months ended June 30, 2021; “Q1 2022” are to the three months ended March 31, 2022; “Q1 2021” are to the three months ended March 31, 2021; “Q4 2021” are to the three months ended December 31, 2021; “Q4 2022” are to the three months ended December 31, 2022; “Q4 2020” are to the three months ended December 31, 2020; “YTD 2022” are to the nine months ended September 30, 2022; “YTD 2021” are to the nine months ended September 30, 2021; “Fiscal 2022” are to the year ending December 31, 2022; “Fiscal 2021” are to the year ended December 31, 2021; and “Fiscal 2019” are to the year ended December 31, 2019.

Cautionary Note Regarding Forward-Looking Information

This MD&A contains forward-looking information and forward-looking statements (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans, objectives and responses to the outbreak of the coronavirus disease (“COVID-19”). Particularly, information regarding our expectations of future results, performance, achievements, facility expansions, leases, platform expansions, acquisitions, public company costs, payment of dividends, prospects, financial targets or outlook, intentions, opportunities, the markets in which we operate and the potential impact of, and response measures to be taken with respect to, COVID-19 is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, “commencing” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company.

This forward-looking information and other forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this MD&A, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to:

- the impact of inflation and rising interest rates together with the threats of stagflation or recession;
- the uncertainties in the global economy created by the war in Ukraine;
- the impact of variation in the value of the Canadian dollar in relation to the U.S. dollar;
- the impact of changing conditions in the healthcare logistics and transportation services market;
- the impact of the COVID-19 pandemic on our operations, business and financial results;
- risks and liabilities associated with the transportation of dangerous goods;
- our ability to comply with U.S. foreign ownership, control or influence mitigation measures;
- our ability to execute our growth strategies;
- increasing competition in the healthcare logistics and transportation services market in which we operate;
- volatility in financial markets;
- changes in the attitudes, financial condition and demand of our target market;
- developments and changes in applicable laws and regulations;
- our ability to source and complete acquisitions;
- our ability to successfully integrate businesses and assets that we acquire and realize synergies;
- our ability to retain existing clients and develop new clientele;
- our ability to retain members of our management team and key personnel;
- increases in driver compensation and the ability to attract and retain employees;
- our ability to expand into additional markets; and
- such other factors discussed in greater detail under “Risk Factors” in this MD&A and in our Annual Information Form dated March 2, 2022 for Fiscal 2021 (the “AIF”) which is available on our profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The opinions, estimates or assumptions referred to above and described in greater detail in “Risk Factors” should be considered carefully by prospective investors.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and allowing investors and others to get a better understanding of our anticipated financial position, results of operations and operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, investors should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this MD&A represents our expectations as of the date of this MD&A (or as of the date they are otherwise stated to be made), and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this MD&A is expressly qualified by the foregoing cautionary statements.

Basis of Presentation

Our unaudited interim condensed consolidated financial statements as at and for the three and nine-month periods ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). Under International Financial Reporting Standards (“IFRS”), additional disclosures are required in the annual financial statements and therefore, our unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the notes to our audited annual consolidated financial statements for the years ended December 31, 2021 and 2020.

Our unaudited interim condensed consolidated financial statements have been prepared using consistent accounting policies and methods used in the preparation of our audited annual consolidated financial statements.

Non-IFRS Measures

This MD&A makes reference to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non-IFRS measures including “EBITDA” and “EBITDA Margin”. These non-IFRS measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and to determine components of management compensation.

For a description of how we define these non-IFRS Measures and an explanation of why the non-IFRS measures provide useful information to investors, please see “How We Assess the Performance of Our Business – Non-IFRS Measures” below.

For quantitative reconciliations of net income to EBITDA for Q3 2022, YTD 2022, Q3 2021 and YTD 2021, please see “Reconciliation of Non-IFRS Measures” below.

Overview

AHG was incorporated under the *Business Corporations Act* (Ontario) on November 12, 2019 with its head office located at 100 Vaughan Valley Blvd, Woodbridge, ON, L4H 3C5. The Company's subordinate voting shares ("Subordinate Voting Shares") are listed on the Toronto Stock Exchange (the "TSX") under the stock symbol "AND".

We are a leading and growing supply chain management company with a platform of customized third-party logistics ("3PL") and specialized transportation solutions for the healthcare sector. We offer services to healthcare manufacturers, wholesalers, distributors and 3PL providers, among others, through a comprehensive platform of high quality, technology-enabled supply chain solutions for a range of products, including: pharmaceuticals, vaccines, biologics, narcotics, precursors, active pharmaceutical ingredients, over-the-counter, natural health, animal health, consumer health, cosmetics, health and beauty aids, and medical devices. We integrate our uniquely designed Canada-wide network of facilities, vehicles, personnel and technology systems into our clients' businesses to offer holistic solutions that span all of our clients' shipping needs and satisfy the requirements of the highly regulated Canadian healthcare sector. During Fiscal 2021, we expanded our specialized transportation capabilities, through acquisitions, into truckload services for the healthcare sector in the United States.

We differentiate our service offerings and deliver value to our clients through our competitive strengths in temperature management, quality assurance and regulatory compliance, technology-enabled visibility throughout the supply chain and security. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. We generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

We believe that we are Canada's only national third-party service provider focused exclusively on delivering customized, end-to-end logistics and specialized transportation solutions to the healthcare sector. Our 3PL services are provided under our Accuristix and LSU brands, through which we provide customized logistics, distribution and packaging solutions to various healthcare manufacturers. Our specialized transportation solutions are offered under our ATS Healthcare, ATS Dedicated and Skelton brands in Canada, where we provide a one-stop shop for our clients' healthcare transportation needs through our specialized air freight forwarding, ground transportation, dedicated delivery and last mile services. We believe we are a national leader in the Canadian healthcare logistics and specialized transportation markets we serve.

We also provide specialized transportation services domestically in the United States under our Skelton USA and Boyle Transportation brands (each as defined below). Skelton USA was launched in 2017 and has been growing rapidly by successfully leveraging its Canadian reputation and brand for expertise in cold chain services. Skelton USA currently serves customers across the United States. Boyle Transportation provides specialized transportation services to clients in the life sciences (approximately 80% of revenue) and government/defense sectors (approximately 20% of revenue). Boyle Transportation adheres to stringent quality and security standards, employs highly trained and dedicated professionals, continually invests in advanced technology and equipment, and has an expansive reach across the United States.

In our healthcare logistics segment, we serve as an extension of our manufacturing clients, leveraging our infrastructure and expertise to manage their supply chain activities, allowing them to focus on other strategic priorities such as sales, marketing, research and development. We focus on serving our logistics clients as comprehensively as possible and incorporate multiple services from all of our related product lines into our customized logistics solutions.

In our specialized transportation segment, we leverage our national infrastructure in Canada to offer coast-to-coast delivery, including specialized facilities, multiple modes of transportation and flexible capacity to accommodate the full range of our clients' logistics and/or transportation needs on an integrated and efficient basis. By combining multiple service offerings, we can effectively provide managed and monitored movement of our clients' temperature sensitive and valuable products through a closed-loop nation-wide system.

Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security are deployed across our Canada-wide network of 31 secure, temperature-controlled facilities, the six third-party owned cross-docks that we operate from and by our team of highly-trained employees. Our security, information and monitoring systems, as well as our temperature management expertise, allow us to meet and exceed Health Canada guidelines and regulations, ensuring the integrity and quality of our clients' temperature sensitive healthcare goods and data.

We also have four facilities in the United States.

Additional information about AHG, including our AIF, can be found on our profile on SEDAR at www.sedar.com or on our website at www.andlauerhealthcare.com.

Summary of Factors Affecting Performance

We believe that our performance and future success depend on a number of factors that present significant opportunities for us. These factors are also subject to a number of inherent risks and challenges, some of which are discussed below and in the "Risk Factors" section of this MD&A and in our AIF.

Service Offering

We believe that offering a platform of services designed specifically for the healthcare sector puts us in a unique position as a provider of supply chain solutions. Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security allow us to provide healthcare clients with specialized, integrated, end-to-end supply chain solutions. Through our five principal, complementary service offerings: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery, we accommodate our clients' specialized supply chain needs on an integrated and efficient basis.

Relationships with Manufacturers and Distributors

We believe that our market position is strengthened by the desire of our clients to increasingly outsource their supply-chain management to specialized service providers with the healthcare quality systems, operational expertise and experience to efficiently optimize their product distribution. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. From manufacturers to distributors to retail locations to front doors across Canada and the United States, we store, transport and monitor and manage the temperature conditions of a range of healthcare products. Our trained personnel comply with healthcare industry regulations and best practices.

New Development Projects

We secure client contract wins as a foundation for growth and then add incremental warehousing and distribution square footage through capital efficient leases. Given the required lead-time to build and license facilities, as we secure new major client contracts, we typically strategically invest in excess capacity in anticipation of growing client needs, as well as new client opportunities, which enables capital efficient growth.

Demographics and Healthcare Spending

We believe that we are strategically positioned to directly benefit from the strong growth expected in the North American healthcare sector, which is driven by a number of favourable trends including an aging population, increased life expectancy, increasing healthcare spending, and an increasing number of healthcare products requiring unique logistics needs. Vaccines and biologics, for example, are generally temperature sensitive and require varying degrees of temperature conditions for transportation and storage.

Regulatory Environment

In order to maintain the safety, quality and efficacy of healthcare products, government regulations set out rules relating to, among other things, the packaging, warehousing, distribution, transportation and temperature monitoring of such products. The pace of introduction and complexity of such regulations has increased in recent years, including through the introduction of, and revisions to, many Health Canada guidelines, such as Health Canada's GUI-0069 - Guidelines for Environmental Control of Drugs During Storage and Transportation ("GUI-0069"), among others. Recognizing the ever-changing regulatory demands on the healthcare sector, we take a proactive approach to stay aligned with regulatory protocols, provide environments that are compliant with Good Manufacturing Practices and offer our clients' real-time monitoring and reporting. By outsourcing their logistics and transportation needs to AHG and our specialized services platform, our clients can focus on their core business.

While we believe the United States does not have as rigorous standards as Canada or Europe regarding the transportation of healthcare products, healthcare manufacturers are demanding high quality temperature control and monitoring as well as security and visibility for their truckload shipments in the United States, which aligns with our specialized transportation solutions. Both Skelton USA and Boyle Transportation comply with United States Pharmacopeia (USP) chapter <1079> Good Storage & Distribution Practices for Drug Products, to the extent applicable for transportation.

Boyle Transportation complies with U.S. Federal Motor Carrier Safety Administration regulations regarding the transportation of hazardous materials. Additionally, the National Industrial Security Program Operating Manual requires that Boyle Transportation be effectively insulated from any Foreign Ownership, Control, or Influence to perform on certain U.S. Department of Defense contracts and operates, under AHG's ownership, pursuant to a pending Special Security Agreement with the U.S. Defense Counterintelligence and Surveillance Agency.

Competition

We believe that we offer a unique set of services in the marketplace and stand apart from other outsourced healthcare service providers and traditional logistics and transportation companies. In particular, we believe our differentiated capabilities, including our temperature management expertise, together with our coast-to-coast distribution network in Canada and multiple service offerings, uniquely positions us within our industry and sets us apart from companies specializing in global integration and supply chain management, national non-temperature managed solutions, regional temperature managed solutions as well as niche service providers and insourced transportation services. Notwithstanding the foregoing, we do compete with

UPS Supply Chain Solutions, Kuehne + Nagel and Lynden Logistics in our delivery of 3PL services, and with UPS, FedEx, Purolator, and several regional players in the specialized transportation space in Canada.

In the United States, Boyle Transportation and Skelton USA compete with a large number of regional carriers as well as national transportation providers, such as FedEx.

Acquisitions

We selectively evaluate strategically compelling acquisition opportunities that leverage or expand our differentiated capabilities. In pursuing potential acquisition opportunities, we assess several criteria to expand our domestic platform, including: (i) complementary tuck-ins; and (ii) entry or expansion into growth verticals, new verticals and new service offerings. We will continue to assess opportunities for expansion in the U.S. or into international markets through existing platforms that align with our core capabilities and existing service offering.

In Q4 2020, we completed two tuck-in acquisitions: TDS Logistics Ltd. (“TDS”), now branded as “ATS Dedicated”, and McAllister Courier Inc. (“MCI”), our first acquisitions as a public company. These two regionally focused temperature-controlled transportation businesses increased the reach of our services and expanded our market presence in Ontario.

On March 1, 2021, we acquired 100% of Skelton Canada Inc. (“Skelton”) and 49% of Skelton USA Inc. (“Skelton USA” and together with Skelton, the “Skelton Companies”) which enhanced our platform with expanded national 2-8°C specialized temperature-controlled capabilities and provided us with a strategic entry into the U.S. market.

On November 1, 2021, we acquired 100% of T.F. Boyle Transportation, Inc. (“Boyle Transportation”), which provides specialized transportation services to clients in the life sciences and government/defense sectors, and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%.

On March 1, 2022, we acquired 100% of Logistics Support Unit (LSU) Inc. (“LSU”). LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution, and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical, and biotechnology sectors.

Management & Employees

Our employee culture is one of our fundamental strengths and a strategic priority. Our employees are passionate about our business and are dedicated to creating and improving solutions for our clients. We empower our employees through training and professional development programs and maintain open lines of communication that encourage our employees to suggest ways in which we can improve our operations. We recognize and celebrate employees who act as leaders within our team and promote movement within our organization in an effort to retain and encourage our top talent. As a result of this collaborative employee culture, we have fostered strong relationships with our employees across our operating segments, none of which are subject to collective bargaining agreements.

Cost Management

In order to provide the services that we offer, we incur various operating costs. These costs include amongst others, labour, rent, fuel, equipment, and insurance. We are susceptible to increases in the price of these items, many of which can fluctuate, often due to factors beyond our control, such as regional and global supply and demand dynamics, political events, global pandemics, terrorist activities, the strength of the Canadian dollar relative to other currencies, and natural disasters.

To mitigate the risk of cost escalation, we focus on operational excellence, synergies between our product lines and cost controls. We rely on, among other things, long-term planning, budgeting processes, and internal benchmarking to achieve our profitability targets. Additionally, we mitigate the risk of inflation by utilizing leases to finance our network of facilities, many of our vehicles and our logistics equipment, as well as by using third-party service providers. We also mitigate our exposure to rising fuel costs through the implementation of fuel surcharge programs, which pass the majority of cost increases to our clients. In addition, we have implemented a number of policies that focus on asset efficiency, including fuel economy, asset utilization, proper repairs and maintenance of equipment, and measured equipment lease renewals. Many of our contracts include cost escalation indexes that provide for annual price adjustments which further protect us from escalating costs.

Financial and Operational Highlights

We refer the reader to the section entitled “How We Assess the Performance of Our Business” of this MD&A for the definition of the items discussed below and, when applicable, to the section entitled “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

Q3 2022 Compared to Q3 2021

Select highlights include the following:

- Revenue increased 58.3% to \$164.9 million, compared to \$104.2 million in Q3 2021;
- Operating income increased 65.9% to \$27.9 million, compared to \$16.8 million in Q3 2021;
- Net income increased 55.9% to \$19.0 million, compared to \$12.2 million in Q3 2021;
- Total comprehensive income increased to \$32.9 million compared with \$12.2 million in Q3 2021;
- EBITDA increased to \$44.1 million compared to \$28.0 million in Q3 2021; and
- EBITDA Margin was 26.7% compared with 26.9% in Q3 2021.
- During Q3 2022, we continued to provide logistics and distribution, specialized transportation, and packaging solutions to certain of our manufacturer, 3PL provider, wholesaler and government clients that are involved in the Canadian supply of COVID-19 vaccines and ancillary products. In Q3 2022, our COVID-19 vaccine-related revenue comprised approximately 2.8% of total revenue compared with approximately 2.5% in Q3 2021.

YTD 2022 Compared to YTD 2021

Select highlights include the following:

- Revenue increased 57.2% to \$482.7 million, compared to \$307.1 million in YTD 2021;
- Operating income increased 57.3% to \$82.2 million, compared to \$52.3 million in YTD 2021;
- Net income increased 53.2% to \$56.5 million, compared to \$36.9 million in YTD 2021;
- Total comprehensive income increased to \$74.0 million, compared with \$36.9 million in YTD 2021;
- EBITDA increased 55.5% to \$129.8 million, compared to \$83.5 million in YTD 2021; and
- EBITDA Margin remained stable at 26.9% compared to 27.2% in YTD 2021.
- On March 1, 2022, we acquired 100% of the issued and outstanding shares of LSU for consideration

of approximately \$30.0 million, before customary working capital adjustments. LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical and biotechnology sectors. We financed the acquisition through the issuance of 154,639 Subordinate Voting Shares and cash of approximately \$19.2 million. We financed the cash portion of the purchase price through a combination of cash on hand and by drawing on our Credit Facilities (as defined below).

How We Assess the Performance of Our Business

We have historically operated and managed our healthcare logistics and specialized transportation segments as separate businesses with separate management teams. Our healthcare logistics segment operates under the brand names Accuristix and LSU; and our specialized transportation segment operates under the brand names ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines. Following our initial public offering (“IPO”) completed December 11, 2019, both Accuristix and ATS Healthcare have continued to operate autonomously, each having its own management. Skelton, which we acquired on March 1, 2021, and Boyle Transportation and Skelton USA, which we acquired on November 1, 2021, which are reported in the specialized transportation segment, also operate autonomously, as they did prior to their respective acquisitions. Similarly, LSU, which we acquired on March 1, 2022, operates autonomously and is included in our healthcare logistics segment. Over time, as we grow, our operating segments may change. If this occurs, we will reflect the change in our reporting practices.

Except for tractors and trailers purchased by Skelton and Boyle Transportation, our operating segments conduct their businesses in a manner that limits capital investments. We prefer to lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe our business model provides us with greater flexibility, cost savings and lower risks, as compared to more capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16 – Leases, leases have been capitalized, resulting in the costs associated with our leases being recorded as depreciation and interest expense. We believe that the cash flows associated with our lease payments are a relevant metric in evaluating the performance of our business.

Revenue

We generate revenue from the provision of supply chain solutions to the Canadian and United States healthcare sectors. Across our healthcare logistics and specialized transportation operating segments, we generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

Our healthcare logistics segment, which offers services under our Accuristix and LSU brands, generates revenue from the provision of logistics and distribution services and packaging solutions to our clients. Services are typically provided under master service agreements with terms that range from three to five years in length. Our logistics contracts typically include a single performance obligation that is satisfied over time as clients simultaneously receive and consume the benefits of our services. For this performance obligation, we recognize revenue at the invoiced amount since this amount corresponds directly to our performance and the value to the client. In some cases, our agreements include other performance obligations related to managing transportation and other client services which are included in the logistics and distribution product. These services are typically priced at their stand-alone selling prices and are recognized over time as the client simultaneously receives and consumes the benefits of our services. Intersegment revenue generated by Credo Systems Canada Inc. from the sale of thermal packaging containers to ATS Healthcare, as well as intra-segment revenue between Accuristix and Nova Pack Ltd. (“Nova Pack”) is eliminated on consolidation.

Our specialized transportation segment, which offers services under our ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines brands, generates revenue from the provision of specialized temperature-controlled, as well as non-temperature controlled, ground transportation, air freight forwarding and dedicated and last mile transportation services to our clients. Certain additional services are provided to clients as requested as part of their transportation contracts, such as chain of custody and other incidental services. Transportation revenue is recognized proportionally as a shipment moves from origin to destination and the related costs are recognized as incurred. Performance obligations are short-term, with transit typically taking less than one week. Generally, clients are billed upon shipment of the freight, and remit payment according to approved payment terms. Intersegment revenue generated by ATS Healthcare and Skelton from the provision of transportation services to Accuristix and LSU, on behalf of their logistics clients, is eliminated on consolidation.

As is customary in our industry, most of our client contracts and transportation pricing terms include fuel-surcharge revenue programs or cost recovery mechanisms to mitigate the effect of fuel price increases over base amounts established in the contract. However, these fuel surcharge mechanisms may not capture the entire amount of changes in fuel prices, and there is also a lag between the payment for fuel and collection of surcharge revenue. Increases or decreases in fuel prices increase or reduce the cost of transportation and services, and will accordingly increase or reduce our revenues and may reduce or increase margins for certain product lines.

Cost of Transportation and Services

Our cost of transportation and services expense includes the cost of providing or procuring freight transportation to our clients. The cost of transportation and services for our specialized transportation segment includes: linehaul costs to connect our national network; pick-up and delivery costs paid to brokers, agents, and our drivers; fuel, toll fees and maintenance costs; and inbound and outbound handling costs which are largely comprised of hourly paid dock labour. The cost of transportation and services for our healthcare logistics segment includes purchased transportation services, including fuel surcharges, sourced from carriers. ATS Healthcare is the largest provider of transportation services to Accuristix and LSU, followed by Skelton. Intersegment purchased transportation expense is eliminated on consolidation.

Direct Operating Expenses

Direct operating expenses are both fixed and variable and consist of operating costs related to our facilities (including our distribution centres, branches and the cross-docks that we operate from). Direct operating expenses consist mainly of personnel costs and facility and equipment expenses such as property taxes, utilities, equipment maintenance and repair, costs of materials and supplies, security and insurance expenses. We note that under IFRS 16 the costs associated with our leases are not recognized in our direct operating expenses.

Selling, General and Administrative Expenses

Selling, General and Administrative (“SG&A”) expenses primarily consist of the cost of salaries and benefits for executive and certain administration functions, including information technology, sales and client service, finance and accounting, professional fees, facility costs, legal costs and other expenses related to the corporate infrastructure required to support our business.

Depreciation & Amortization

Depreciation and amortization charges comprise non-cash charges expensed on the statement of income and comprehensive income to spread the purchase price of assets over their useful lives. Within both of our operating segments, we lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe this approach provides us with greater flexibility and lower risks and results in cost savings as compared to capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16, leases have been capitalized, resulting in depreciation and interest expense rather than direct operating expense.

Operating Income

Operating Income measures the amount of profit derived from our operations after deducting operating expenses such as cost of transportation and services, direct operating expense, SG&A, and depreciation and amortization. We do not typically measure “cost of sales or gross profit” as we are a service business.

Share of Profit of Equity-Accounted Investee, Net of Tax

Following the acquisition of a 49% interest in Skelton USA on March 1, 2021, we determined that AHG did not control Skelton USA until the remaining 51% of Skelton USA was acquired on November 1, 2021. Accordingly, between March 1, 2021 and October 31, 2021, we accounted for our investment in Skelton USA using the equity method of accounting. Under the equity method of accounting, an equity investment is initially recorded at cost and is subsequently adjusted to reflect the investor’s share of the net profit or loss of the investee. From November 1, 2021 forward, Skelton USA is consolidated with AHG in accordance with IFRS 10 – Consolidated Financial Statements.

Interest Expense

Interest expense comprises interest charged to the statement of income and comprehensive income primarily in connection with leased facilities and equipment under IFRS 16, and for borrowings under our Credit Facilities.

Interest Income

Interest income comprises interest earned on cash and cash equivalents. In Fiscal 2021, we sub-leased a facility to a third party that had previously been classified as a right-of-use asset. We derecognized the net book value from right-of-use assets and established a net investment sub-lease in connection with this facility. Interest income includes interest generated by this sub-lease.

Other Income/Expense

Other income (expense) comprises income or expenses that do not arise from our main business, such as exchange gains (losses) and gains (losses) resulting from the sale of property, plant and equipment and certain other insignificant sources.

Income Tax Expense/Recovery

Income tax expense (recovery) comprises the amount that we have recognized in the accounting period related to our taxable income. Our effective tax rate is generally close to the statutory rate, but certain differences between income for tax and accounting income are recognized in the deferred income tax provision.

Foreign Currency Translation Adjustment

In preparing our consolidated financial statements, the financial statements of each entity are translated into Canadian dollars. The assets and liabilities of foreign operations are translated to Canadian dollars at exchange rates as at the balance sheet date. Revenues and expenses of foreign operations are translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction. Foreign exchange differences are recognized in other comprehensive income and accumulated in equity in accumulated other comprehensive income.

Non-IFRS Measures

EBITDA

We define EBITDA as net income for the period before: (i) income tax expense (recovery); (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization. Net income is the most directly comparable IFRS financial measure disclosed in our financial statements to which EBITDA relates, and a reconciliation with this measure is presented under “Reconciliation of Non-IFRS Measures”.

We believe EBITDA is a useful measure to assess our financial performance because it provides a more relevant picture of operating results by excluding the effects of expenses that are not reflective of our underlying business performance.

EBITDA Margin

We define EBITDA Margin as EBITDA divided by revenue. EBITDA Margin represents a measure of our profitability expressed as a percentage of revenue.

We believe EBITDA Margin is a useful measure to assess our financial performance because it helps quantify our ability to convert revenues generated from clients into EBITDA.

Selected Consolidated Financial Information

The following table summarizes our results of operations for the periods indicated. The selected consolidated financial information for Q3 2022, Q3 2021, YTD 2022 and YTD 2021 has been derived from our unaudited interim condensed consolidated financial statements and the related notes thereto. See “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

Consolidated Statements of Income and Comprehensive Income

(\$CAD 000s)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Revenue				
Logistics & distribution	42,574	28,953	117,664	85,734
Packaging solutions	5,443	4,504	17,365	15,721
Healthcare Logistics segment	48,017	33,457	135,029	101,455
Ground transportation	105,353	60,750	309,180	176,602
Air freight forwarding	7,704	6,155	26,834	19,190
Dedicated and last mile delivery	16,980	13,348	49,540	37,978
Intersegment revenue	(13,156)	(9,511)	(37,932)	(28,135)
Specialized Transportation segment	116,881	70,742	347,622	205,635
Total revenue	164,898	104,199	482,651	307,090
Operating expenses				
Cost of transportation and services	81,034	47,501	236,508	136,076
Direct operating expense	28,262	21,393	81,291	63,582
Selling, general and administrative expenses	11,294	8,259	34,676	26,148
Depreciation & amortization	16,448	10,250	47,997	29,033
	137,038	87,403	400,472	254,839
Operating income	27,860	16,796	82,179	52,251
Share of profit of equity-accounted investee, net of tax	-	1,004	-	2,098
Interest expense	(1,746)	(1,570)	(4,991)	(4,654)
Interest income	86	25	203	166
Other (expense) income	(236)	(24)	(391)	104
Income tax expense	(6,969)	(4,043)	(20,549)	(13,115)
Net income	18,995	12,188	56,451	36,850
Other comprehensive income				
Net income	18,995	12,188	56,451	36,850
Foreign currency translation adjustment	13,907	-	17,515	-
Total comprehensive income	32,902	12,188	73,966	36,850
Earnings per share				
Earnings per share – basic	\$ 0.45	\$ 0.32	\$ 1.35	\$ 0.96
Earnings per share – diluted	\$ 0.44	\$ 0.31	\$ 1.32	\$ 0.94
Select financial metrics¹				
EBITDA	44,072	28,026	129,785	83,486
EBITDA Margin	26.7%	26.9%	26.9%	27.2%

¹ These are non-IFRS financial measures. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on these measures.

Consolidated Balance Sheets

(\$CAD 000s)	As At September 30,	
	2022	2021
Select financial position data		
Total assets	708,924	395,999
Total non-current liabilities	192,068	163,073

Consolidated Statements of Changes in Equity

(\$CAD 000s)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Select financial data				
Dividends	2,930	1,924	7,949	5,771

Reconciliation of Non-IFRS Measures

The following table provides a reconciliation of net income to EBITDA for the periods indicated:

(\$CAD 000s)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Net income	18,995	12,188	56,451	36,850
Income tax expense	6,969	4,043	20,549	13,115
Interest expense	1,746	1,570	4,991	4,654
Interest income	(86)	(25)	(203)	(166)
Depreciation and amortization	16,448	10,250	47,997	29,033
EBITDA¹	44,072	28,026	129,785	83,486

¹ This is a non-IFRS financial measure. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on this measure.

Results of Operations

Three months ended September 30, 2022 compared with 2021

The following section provides an overview of our financial performance for Q3 2022 compared to Q3 2021.

Revenue

Revenue for Q3 2022 increased by 58.3% to \$164.9 million, compared with \$104.2 million in Q3 2021. Our LSU, Skelton USA and Boyle Transportation acquisitions accounted for approximately \$43.4 million of the \$60.7 million increase with the remaining growth attributable to organic growth and fuel surcharge revenue as described below. Approximately 2.8% of our consolidated revenue for Q3 2022, compared with approximately 2.5% for Q3 2021, was generated by working with manufacturer, 3PL, distributor, and government clients involved in the supply of vaccines and related products in connection with the COVID-19 pandemic.

Healthcare Logistics Segment

Revenue in our healthcare logistics segment for Q3 2022 was \$48.0 million, an increase of 43.5%, or approximately \$14.6 million, compared with Q3 2021. The increase in revenue for this segment was primarily driven by the factors set out below.

Logistics & Distribution

Logistics and distribution revenue for Q3 2022 was \$42.6 million, an increase of 47.0%, or approximately \$13.6 million, compared with Q3 2021. Approximately \$8.9 million of the increase is attributable to our acquisition of LSU on March 1, 2022, with the remaining increase comprising organic growth in outbound order handling activities for Accuristix and increases in transportation billings impacted by fuel surcharge programs from carriers, which are passed on to customers.

Packaging Solutions

Packaging revenue for Q3 2022 was \$5.4 million, an increase of 20.8%, or approximately \$0.9 million, compared with Q3 2021. Our packaging revenue exceeded what we generated for the same period during Fiscal 2019, prior to the global COVID-19 pandemic, for the second quarter in a row.

Specialized Transportation Segment

Revenue in our specialized transportation segment for Q3 2022 was \$116.9 million, an increase of 65.2%, or approximately \$46.1 million, compared with Q3 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Ground Transportation

Ground transportation revenue for Q3 2022 was \$105.4 million, an increase of 73.4%, or approximately \$44.6 million, compared with Q3 2021. The increase reflects incremental revenue from our Skelton USA, and Boyle Transportation acquisitions of approximately \$34.5 million, representing an increase of 56.8%, with the remainder attributable to organic growth and higher fuel costs passed through to customers as a component of our pricing.

Air Freight Forwarding

Air freight forwarding revenue for Q3 2022 was \$7.7 million, an increase of 25.2%, or approximately \$1.5 million, compared with Q3 2021. The increase is primarily attributable to higher fuel costs passed on to customers as a component of our pricing.

Dedicated and Last Mile Delivery

Dedicated and last mile delivery revenue for Q3 2022 was \$17.0 million, an increase of 27.2%, or approximately \$3.6 million, compared with Q3 2021. Approximately 50% of the increase is attributable to organic growth with the remaining 50% attributable to increases in fuel costs passed on to customers.

Cost of Transportation and Services

Cost of transportation and services for Q3 2022 was \$81.0 million, or 49.1% of revenue, compared with \$47.5 million, or 45.6% of revenue, for Q3 2021. The higher cost of transportation and services is primarily attributable to the acquisitions of Skelton USA and Boyle Transportation, and higher fuel costs in line with the increases in revenue related to fuel prices. The increase in the operating ratio for Q3 2022 as compared to Q3 2021 reflects our Skelton USA and Boyle Transportation acquisitions, which have increased the relative proportion of our specialized transportation segment as a percentage of our total consolidated revenue and cost profiles.

Direct Operating Expenses

Direct operating expenses for Q3 2022 were \$28.3 million, or 17.1% of revenue, compared with \$21.4 million, or 20.5% of revenue, for Q3 2021. The \$6.9 million increase is primarily attributable to outbound volume growth in our Accuristix logistics and distribution operations, and our acquisition of LSU on March 1, 2022. Our specialized transportation acquisitions (Skelton USA and Boyle Transportation) have lower facility-related costs compared to our healthcare logistics segment, which resulted in a lower direct operating expense operating ratio in Q3 2022 as compared to Q3 2021.

During Q4 2021, the Canada Emergency Wage Subsidy (“CEWS”) program concluded. In Q3 2021, we recognized \$0.3 million, or 0.3% of revenue, as a reduction to payroll expense for CEWS compared to \$nil in Q3 2022.

Selling, General and Administrative Expenses

SG&A expenses for Q3 2022 were \$11.3 million, or 6.8% of revenue, compared with \$8.3 million, or 7.9% of revenue, for Q3 2021. The \$3.0 million increase in Q3 2022 is primarily attributable to our acquisitions (LSU, Skelton USA, and Boyle Transportation). The decrease in SG&A expenses as a percentage of revenue reflects operating leverage generated within SG&A functions compared to revenue growth.

Depreciation and Amortization

Depreciation and amortization for Q3 2022 was \$16.4 million, an increase of 60.5% compared with \$10.3 million for Q3 2021. The increase is primarily attributable to depreciation and amortization related to our LSU, Skelton USA, and Boyle Transportation acquisitions.

Share of Profit of Equity-Accounted Investee, Net of Tax

For Q3 2021, our 49% share of total comprehensive income of Skelton USA was \$1.0 million. On November 1, 2021, Skelton USA became a wholly-owned subsidiary and is included in our consolidated results for Q3 2022.

Interest Expense

Interest expense for Q3 2022 was \$1.7 million compared with \$1.6 million for Q3 2021. Interest expense related to leased facilities and equipment comprises the majority of interest expense; however, \$0.5 million of interest expense for Q3 2022 was incurred in connection with our Credit Facilities, compared with \$0.4 million in Q3 2021.

At this time, we expect to continue to hold debt under the Term Facility (as defined below), which does not have any repayment schedule except as a single repayment at the end of the four-year term and will incur interest expense until maturity on March 1, 2025.

Interest Income

Interest income for Q3 2022 and Q3 2021 was negligible. Interest income is generated on our cash and cash equivalents balances and is earned in connection with our sub-lease of a facility to a third party.

Other Income/Expense

Other expense was approximately \$0.2 million for Q3 2022, compared with effectively \$nil in Q3 2021. These amounts are immaterial to our overall performance for Q3 2022 and Q3 2021.

Income Tax Expense

Income tax expense for Q3 2022 was \$7.0 million compared with \$4.0 million in Q3 2021. Our effective tax rate is close to the statutory rate of 26.5% for Q3 2022 and Q3 2021 after removing the effect of non-deductible share-based compensation expenses, and (for Q3 2021 only) the inclusion of the share of profit of our equity-accounted investee, net of tax.

Operating Income and Net Income

Operating income for Q3 2022 was \$27.9 million, an increase of \$11.1 million, or 65.9%, compared with \$16.8 million for Q3 2021. Approximately \$4.8 million of the increase is attributable to our acquisitions of LSU, Skelton USA, and Boyle Transportation, with the remainder attributable to organic growth.

Income before tax for the specialized transportation segment was \$19.6 million for Q3 2022, compared with \$12.8 million for Q3 2021. Approximately \$3.6 million of the increase is attributable to our acquisitions of Skelton USA and Boyle Transportation, with the remainder attributable to organic growth.

Income before tax for the healthcare logistics segment was \$6.3 million for Q3 2022 compared with \$3.6 million for Q3 2021. The increase reflects greater outbound order handling activities in line with our revenue growth for the period and the acquisition of LSU on March 1, 2022.

Net income for Q3 2022 was \$19.0 million compared with \$12.2 million in Q3 2021. Higher segment net income before eliminations for both our healthcare logistics and specialized transportation operating segments contributed to the increased profit on a consolidated basis.

Foreign Currency Translation Adjustment

Foreign exchange differences of \$13.9 million have been recognized in other comprehensive income for Q3 2022. This reflects assets and liabilities of Skelton USA and Boyle Transportation which have been translated to Canadian dollars at the exchange rate as at September 30, 2022 and revenues and expenses which have been translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction.

Total Comprehensive Income

Total comprehensive income attributable to the owners of the Company was \$32.9 million for Q3 2022 compared to \$12.2 million for Q3 2021. Total comprehensive income differs from net income due to the acquisition of foreign operations (Skelton USA and Boyle Transportation) resulting in foreign currency translation adjustments as described above.

EBITDA

EBITDA for Q3 2022 increased by 57.3% to \$44.1 million, from \$28.0 million for Q3 2021. EBITDA increased over Q3 2021 due to the factors discussed above and reflects the incremental contributions of our acquisitions and organic growth in both of our operating segments.

EBITDA Margin

EBITDA Margin for Q3 2022 was 26.7%, compared with 26.9% for Q3 2021. Approximately 1.0% of EBITDA margin in Q3 2021 was attributable to the impact of the share of profit of Skelton USA, which was accounted for as an equity investee during that period. Q3 2022 EBITDA Margin was impacted by several offsetting factors including the effect of increased fuel prices as a component of revenue and the elimination of inter-segment transactions. The performance of our two operating segments continues to result in strong and stable EBITDA Margins. The margin profiles of Skelton USA and Boyle Transportation are in line with AHG's consolidated EBITDA range, and LSU achieved a margin consistent with our logistics and distribution product line.

Nine months ended September 30, 2022 compared with 2021

The following section provides an overview of our financial performance for YTD 2022 and YTD 2021.

Revenue

Revenue for YTD 2022 increased by 57.2% to \$482.7 million compared with \$307.1 million in YTD 2021. Revenue attributable to our acquisitions of Skelton USA, Boyle Transportation and LSU accounted for \$159.6 million of the \$175.6 million increase from YTD 2021 to YTD 2022.

Healthcare Logistics Segment

Revenue in our healthcare logistics segment for YTD 2022 was \$135.0 million, an increase of 33.1%, or approximately \$33.6 million, compared with YTD 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Logistics & Distribution

Logistics and distribution revenue for YTD 2022 was \$117.7 million, an increase of 37.2%, or approximately \$31.9 million, compared with YTD 2021. Our acquisition of LSU on March 1, 2022 contributed approximately \$18.9 million of the increase, with the remaining increase attributable to volume growth within our existing client base and rate increases primarily related to transportation billings impacted by fuel surcharge programs from carriers, which are passed on to customers.

Packaging Solutions

Packaging revenue for YTD 2022 was \$17.4 million, an increase of 10.5% or approximately \$1.6 million compared with YTD 2021. During Q3 2022, our packaging revenue exceeded what we generated for the same period during Fiscal 2019, prior to the onset of the COVID-19 pandemic, for the second consecutive quarter.

Specialized Transportation Segment

Revenue in our specialized transportation segment for YTD 2022 was \$347.6 million, an increase of 69.0%, or approximately \$142.0 million, compared with YTD 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Air Freight Forwarding

Air freight forwarding revenue for YTD 2022 was \$26.8 million, an increase of 39.8%, or approximately \$7.6 million, compared with YTD 2021. The increase was attributable to an approximate 17% volume increase in YTD 2022 as compared to YTD 2021, while the remainder of the increase was related to increased revenue related to fuel cost increases in Q3 2022, which are passed on to customers.

Ground Transportation

Ground transportation revenue for YTD 2022 was \$309.2 million, an increase of 75.1%, or approximately \$132.6 million, compared with YTD 2021. Approximately \$97.4 million, or 55.1%, of the increase is attributable to our Skelton USA and Boyle Transportation acquisitions. The remaining increase is primarily attributable to fuel-related revenue driven by increased fuel surcharges.

Dedicated and Last Mile Delivery

Dedicated and last mile delivery revenue for YTD 2022 was \$49.5 million, an increase of 30.4%, or approximately \$11.6 million, compared with YTD 2021. The increase is primarily attributable to expanded routes for existing clients and increases in fuel costs passed on to customers.

Cost of Transportation and Services

Cost of transportation and services for YTD 2022 was \$236.5 million, or 49.0% of revenue, compared with \$136.1 million, or 44.3% of revenue, for YTD 2021. The increase in the operating ratio for YTD 2022 as compared to YTD 2021 reflects the addition of Skelton USA and Boyle Transportation cost profiles. The increase in cost of transportation and services also reflects increased volume related to ATS Healthcare and Skelton, and higher fuel costs for Q3 2022 in line with the increase in ground transportation revenue related to fuel for Q3 2022.

Direct Operating Expenses

Direct operating expenses for YTD 2022 were \$81.3 million, or 16.8% of revenue, compared with \$63.6 million, or 20.7% of revenue, for YTD 2021. Approximately \$9.7 million of the \$17.7 million increase is attributable to our LSU acquisition, with the remaining increase attributable to increased volumes of inbound and outbound receiving and shipping volumes at Accuristix. Our specialized transportation acquisitions (Skelton USA and Boyle Transportation) have lower facility-related costs compared to our healthcare logistics segment, which resulted in a lower direct operating expense operating ratio in YTD 2022 as compared to YTD 2021.

During YTD 2021, we qualified for the CEWS program in connection with our packaging operations. A total of \$1.2 million, or 0.4% of revenue, was recognized as a reduction of direct operating expenses for YTD 2021 for assistance received from the CEWS program compared to \$nil in YTD 2022.

Selling, General and Administrative Expenses

SG&A expenses for YTD 2022 were \$34.7 million, or 7.2% of revenue, compared with \$26.1 million, or 8.5% of revenue, for YTD 2021. The increase in SG&A expenses is primarily attributable to the acquisitions of LSU, Skelton USA and Boyle Transportation. SG&A expenses for YTD 2022 include share-based compensation arrangements of approximately \$1.0 million, or 0.2% of revenue compared to \$1.4 million, or 0.5% of revenue for YTD 2021, which contributed to lower SG&A expenses as a percentage of revenue for YTD 2022 as compared to YTD 2021. These share-based compensation arrangements relate to the initial stock option grants to our directors and senior management team, and deferred share unit grants to our directors, which are intended to provide further alignment with shareholders.

Depreciation and Amortization

Depreciation and amortization for YTD 2022 was \$48.0 million, an increase of 65.3%, or \$19.0 million, compared with \$29.0 million for YTD 2021. The acquisitions of LSU, Skelton USA and Boyle Transportation accounted for \$16.5 million of the increase, with the remaining \$2.5 million increase attributable to leases for new right-of-use logistics and transportation equipment to support growth in our specialized transportation segment.

Other Income/Expense

Other expense for YTD 2022 was \$0.4 million compared with other income of \$0.1 million for YTD 2021. These amounts are immaterial to our overall performance for these periods.

Interest Income

Interest income for YTD 2022 was \$0.2 million compared with \$0.2 million for YTD 2021. Interest income is generated on our cash and cash equivalents balances and is earned in connection with our sub-lease of a facility to a third party.

Interest Expense

Interest expense for YTD 2022 was \$5.0 million compared with \$4.7 million for YTD 2021. Interest expense related to leased facilities and equipment comprises the significant majority of interest expense; however, \$1.3 million of interest expense was incurred in YTD 2022 in connection with the Credit Facilities which were entered into at the time of our IPO and increased in connection with the acquisition of Skelton, compared to \$1.0 million in YTD 2021. At this time, we expect to continue to hold debt under the Term Facility, which does not have any repayment schedule except as a single repayment at the end of the term and will incur interest expense on the Term Facility for the duration of the term which concludes on March 1, 2025.

Income Tax Expense

Income tax expense for YTD 2022 was \$20.5 million compared with \$13.1 million for YTD 2021. Our effective tax rate is close to the statutory rate of approximately 26.5% for both YTD 2022 and YTD 2021 after removing the effect of non-deductible share-based compensation expenses, and (for YTD 2021 only) the inclusion of the share of profit of our equity-accounted investee, net of tax.

Operating Income and Net Income

Operating income for YTD 2022 was \$82.2 million, an increase of \$29.9 million, or 57.3%, compared with \$52.3 million for YTD 2021. Approximately \$13.0 million of the increase is attributable to our acquisitions of LSU, Skelton USA, and Boyle Transportation, with the remainder attributable to organic growth.

Income before tax for the specialized transportation segment was \$61.0 million for YTD 2022, compared with \$39.2 million for YTD 2021. Approximately \$10.8 million of the increase is attributable to our acquisitions of Skelton USA and Boyle Transportation, with the remainder attributable to organic growth.

Income before tax for the healthcare logistics segment was \$16.3 million for YTD 2022 compared with \$11.8 million for YTD 2021. The increase reflects greater outbound order handling activities in line with our revenue growth for the period and the acquisition of LSU on March 1, 2022.

Net income for YTD 2022 increased by 53.2%, or \$19.6 million, to \$56.5 million, from \$36.9 million for YTD 2021. Higher segment net income before eliminations for both our healthcare logistics and specialized transportation operating segments contributed to the increased profitability on a consolidated basis.

Foreign Currency Translation Adjustment

Foreign exchange differences of \$17.5 million have been recognized in other comprehensive income for YTD 2022. This reflects assets and liabilities of Skelton USA and Boyle Transportation which have been translated to Canadian dollars at the exchange rate as at September 30, 2022 and revenues and expenses which have been translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction.

Total Comprehensive Income

Total comprehensive income attributable to the owners of the Company was \$74.0 million for YTD 2022 compared to \$36.9 million for YTD 2021. Total comprehensive income differs from net income due to the acquisition of foreign operations (Skelton USA and Boyle Transportation) resulting in foreign currency translation adjustments as described above.

EBITDA

EBITDA for YTD 2022 increased by 55.5%, to \$129.8 million, from \$83.5 million for YTD 2021. The increase in EBITDA was due to the factors discussed above.

EBITDA Margin

EBITDA Margin for YTD 2022 was 26.9%, compared with 27.2% for YTD 2021 and is at the higher end of our historical range of expected EBITDA Margins. Operating leverage was created in both of our operating segments as a result of volume growth, the continued management of our variable costs, and through our strategic acquisitions of LSU, Skelton USA and Boyle Transportation. YTD 2021 EBITDA Margin reflects \$2.1 million or approximately 0.7% related to the equity accounting treatment for Skelton USA.

Summary of Quarterly Results

While there is no significant seasonality to our business, our results are impacted by our clients' storage and shipping activities throughout the year as well as the timing of new client implementations or exits.

The table below sets out our results for each of the eight most recently completed quarters (unaudited):

(\$CAD 000s) except per share data	Q3-22	Q2-22	Q1-22	Q4-21	Q3-21	Q2-21	Q1-21	Q4-20
Total revenue	164,898	169,402	148,351	133,025	104,199	107,125	95,766	86,632
Operating income	27,860	30,157	24,162	21,452	16,796	18,792	16,663	14,281
Net income	18,995	20,985	16,471	53,104	12,188	13,051	11,611	13,869
Total comprehensive income	32,902	27,560	13,504	55,993	12,188	13,051	11,611	13,869
EBITDA	44,072	46,327	39,386	73,691	28,026	29,973	25,487	21,964
Earnings per share – basic	\$0.45	\$ 0.50	\$ 0.39	\$ 1.29	\$ 0.32	\$ 0.34	\$ 0.31	\$ 0.37
Earnings per share - diluted	\$0.44	\$ 0.49	\$ 0.39	\$ 1.26	\$ 0.31	\$ 0.33	\$ 0.30	\$ 0.36

Generally, revenue has trended upwards through the past eight quarters reflecting both increased shipping volumes from our clients as well as the impact of price increases which are contractually implemented in both of our operating segments annually or as contracts are renegotiated. Our acquisitions in the past eight quarters have driven step change increases in revenue as well. Revenue in Q3 2022 and Q2 2022 reflect increases in fuel prices which are passed on to customers as a component of our pricing. Revenue in Q3 2022 was slightly lower than Q2 2022 revenue as average diesel fuel prices were lower by approximately 7% than in Q2 2022.

Revenue in the most recent four quarters includes the consolidation of LSU (for YTD 2022 only), Skelton USA and Boyle Transportation, resulting in approximately \$43.4 million, \$40.3 million, \$32.5 million and \$19.0 million of acquired revenue for such quarters, respectively. During YTD 2022 we continued to support the distribution of COVID-19 vaccines and related products, such as test kits and personal protective equipment. Revenue in Q3 2021 was slightly lower than Q2 2021 revenue as activity related to COVID-19 vaccines was higher in Q2 2021.

Following several quarters which were impacted by the COVID-19 pandemic, shipping volumes from Q4 2020 through to Q1 2021 returned to more normalized pre-pandemic levels with year-over-year increases averaging in the mid-single digit percentages.

Operating income, net income, comprehensive income, and EBITDA have continued to perform consistently with revenue growth over the past eight quarters and have effectively absorbed the IPO and incremental costs associated with being a public company since December 11, 2019.

We completed our acquisition of Skelton USA in two separate transactions (49% on March 1, 2021 and the remaining 51% on November 1, 2021). Accordingly, in accordance with IFRS 3 – Business Combinations, we re-measured our previously held equity interest in Skelton USA at its estimated fair value on November 1, 2021 resulting in a gain of \$37.9 million being recognized in income from the step acquisition. Net income, total comprehensive income, EBITDA and earnings per share figures for Q4 2021 reflect this gain.

Liquidity & Capital Resources

Overview

Our principal uses of funds are for operating expenses, taxes, interest, capital expenditures, lease payments and dividends. We believe that cash generated from our operations, together with amounts available under our Credit Facilities will be sufficient to meet our future operating expenses, taxes, interest, capital expenditures, lease payments and any dividends that may be declared by our board of directors. However, our ability to fund operating expenses, taxes, interest, capital expenditures and future lease payments will depend on, among other things, our future operating performance, which will be affected by general economic, financial and other factors, including factors beyond our control. See “Accounting Classifications and Fair Values”, “Summary of Factors Affecting Performance” and “Risk Factors” in this MD&A. We review potential acquisitions and investment opportunities in the normal course of our business and may make select acquisitions and investments to implement our growth strategy when suitable opportunities arise.

Our tuck-in acquisitions of TDS and MCI in October 2020 for a purchase price of approximately \$15.9 million in cash were funded from existing cash flow from operations. We financed the acquisitions of Skelton and the initial 49% of Skelton USA in March 2021 through a combination of cash on hand and by drawing \$50.0 million on our Revolving Credit Facility and \$25.0 million on our Term Facility, and by issuing \$25.0 million of Subordinate Voting Shares to the shareholders of Skelton and Skelton USA. During Fiscal 2021, we repaid \$39.0 million of the \$50.0 million initially drawn on our Revolving Credit Facility in connection with the Skelton and Skelton USA acquisitions.

On November 1, 2021, we completed the acquisitions of 100% of Boyle Transportation and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%. The aggregate purchase price for the acquisition of Boyle Transportation was approximately US\$83.0 million (\$104.7 million), of which approximately US\$63.0 million was paid in cash and US\$20.0 million was satisfied by issuing 522,116 Subordinate Voting Shares to the shareholders of Boyle Transportation. The aggregate purchase price for the acquisition of the remaining 51% interest in Skelton USA was approximately \$44.8 million, of which \$19.8 million was paid in cash and \$25 million was satisfied by issuing 518,672 Subordinate Voting Shares to the shareholders of Skelton USA. The cash portion of the purchase price for each acquisition was funded through the Offering, pursuant to which AHG issued 2.0 million Subordinate Voting Shares from treasury for gross proceeds of \$96.4 million to the Company, with the remaining amounts funded from existing cash flow from operations.

On March 1, 2022, we acquired LSU for approximately \$29.2 million. We satisfied the purchase price through the issuance of 154,639 Subordinate Voting Shares to the shareholders of LSU and cash of approximately \$21.7 million comprising the cash portion of the purchase price net of provisional customary working capital adjustments. We financed the cash portion of the purchase price through a combination of cash on hand and by drawing on our Revolving Credit Facility. During YTD 2022, we repaid \$23.0 million of the amounts drawn on our Revolving Credit Facility in connection with the LSU and Skelton acquisitions. As at September 30, 2021, there was \$nil drawn on our Revolving Credit Facility.

Working Capital

The following table presents our working capital position as at September 30, 2022 and 2021:

(\$CAD 000s)	As at September 30,	
	2022	2021
Cash and cash equivalents	50,683	14,313
Trade and other receivables	98,987	76,861
Inventories	3,268	1,768
Prepaid expenses and other	6,132	3,845
Due from related parties	54	2,501
Revolving credit facility	-	(20,000)
Accounts payable and accrued liabilities	(43,562)	(30,397)
Current portion of lease liabilities	(27,279)	(25,667)
Income taxes payable	(19,475)	(4,716)
Working Capital	68,808	18,508

As at September 30, 2022, we had working capital of \$68.8 million compared with working capital of \$18.5 million as at September 30, 2021. The \$50.3 million increase in working capital is primarily attributable to the increased scale of our business since the acquisitions of LSU, Skelton USA, and Boyle Transportation and the repayment of amounts drawn on our Revolving Credit Facility. Although the Revolving Credit Facility does not have any repayment terms, we classify amounts drawn on it in current liabilities as we expect to reduce any amounts drawn within the following twelve months with free cash flow generated from operations. Other working capital amounts reflect the consolidation of our acquisitions.

Credit Facilities

We entered into credit facilities upon closing of our IPO, comprised of a revolving credit facility (the “Revolving Credit Facility”) in the aggregate principal amount of up to \$75.0 million and a term facility (the “Term Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”) in the aggregate principal amount of up to \$25.0 million. On February 19, 2021, in connection with our acquisitions of Skelton and 49% of Skelton USA, we amended our Credit Facilities to increase the amounts available to be drawn under the Revolving Credit Facility and the Term Facility each by \$25.0 million. The amended Credit Facilities comprise a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The remaining terms and conditions of the Credit Facilities remain unchanged, except that they will mature and be due and payable on March 1, 2025. As at September 30, 2022, the aggregate amount outstanding before financing costs under the Credit Facilities was \$50.0 million under the Term Facility and \$nil under the Revolving Credit Facility.

The Revolving Credit Facility is available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. The Term Facility was drawn in a single Canadian dollar advance of \$25.0 million on closing of the IPO by way of prime rate loans and was subsequently converted to bankers’ acceptances and increased by a single Canadian dollar advance of \$25.0 million by way of bankers’ acceptances in connection with the Skelton acquisitions on March 1, 2021.

The Credit Facilities are subject to customary negative covenants and include financial covenants requiring us to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. As at September 30, 2022, we were in compliance with all of the covenants under the Credit Facilities.

In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities, or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As of the date of this MD&A, this accordion feature remains uncommitted.

Capital Expenditures

Capital expenditures for Q3 2022 and YTD 2022 were \$7.6 million and \$14.7 million, respectively, compared with \$1.3 million and \$5.1 million for Q3 2021 and YTD 2021, respectively. Capital expenditures have historically been funded through cash flows from operations. We have traditionally divided our capital expenditures into two subcategories, capital expenditures (maintenance) and capital expenditures (growth), which are further detailed below.

Skelton and Boyle Transportation have traditionally purchased their fleets, whereas ATS Healthcare and Skelton USA have historically leased their equipment. As our operating segments run autonomously, we expect these entities to continue their past practices in the foreseeable future. Accordingly, management expects that capital expenditures will increase in Fiscal 2022 relative to Fiscal 2021 as Skelton and Boyle Transportation invest to support growth and to maintain their fleets. Otherwise, there are no known trends or expected fluctuations in our capital resources, including expected changes in the mix and relative cost of these resources.

Capital Expenditures (Maintenance)

Maintenance capital expenditures refers to capital expenditures necessary for us to sustain our assets in order to continue operating in our current form. We generally seek to maintain our facilities and equipment at a level consistent with the needs of the sector we operate within and ensure that preventative maintenance programs are in place to achieve the performance expected from our facilities and equipment. Outlays for maintenance capital expenditures for Q3 2022 and YTD 2022 were \$4.7 million and \$6.3 million, respectively, compared with \$0.4 million and \$1.9 million, respectively, for Q3 2021 and YTD 2021. These capital expenditures were funded through cash flows from operations.

Capital Expenditures (Growth)

Growth capital expenditures comprises expenditures on new assets that are intended to grow our productive capacity. These capital expenditures are made to acquire or expand leasehold improvements, transportation and logistics equipment (including pick-up and delivery equipment, warehouse racking, material handling equipment, warehouse automation equipment and specialized logistics equipment such as coolers or vaults, among others), furniture and fixtures, and computer equipment to support new contracts or additional volume from new business. Outlays for growth capital expenditures for Q3 2022 and YTD 2022 were \$2.9 million and \$8.4 million, respectively, compared with \$0.8 million and \$3.3 million in Q3 2021 and YTD 2021, respectively. Growth capital expenditures can range from \$5.0 million to over \$15.0 million in any given fiscal year, depending on the underlying expansion need. Growth capital expenditures have also historically been funded through cash flows from operations. Growth capital expenditures for Q3 2022 and YTD 2022 relate primarily to the purchase of tractors and trailers by Skelton and Boyle Transportation and include approximately \$0.2 million for Q3 2022 and \$1.4 million for YTD 2022 related to warehouse equipment for Accuristix. Growth capital expenditures for Q3 2021 and YTD 2021 were attributable to the purchase of tractors and trailers by Skelton (with respect to Q3 2021 only) and leasehold improvements, warehouse racking, material handling equipment, and furniture and fixtures related to our healthcare logistics facility in Brampton, Ontario.

In December 2020, we signed an agreement to implement the Tecsys Itopia® platform, a best-in-class healthcare logistics ‘software as a service’ platform, to replace our prior warehouse management system (“WMS”). Tecsys Inc. is an industry-leading supply chain management software company, and its technology stack will provide us with enhanced warehouse management and transportation management capabilities as well as end-to-end analytics and business intelligence. Our first client is expected to be live on our new WMS in Q4 2022. In YTD 2022 we capitalized \$1.4 million to intangible assets in connection with our new WMS.

Cash Flows

The following table presents cash flows for the three and nine months ended September 30, 2022 and 2021:

(\$CAD 000s)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Cash flows				
Cash from Operating Activities	37,380	19,529	100,383	55,742
Cash (used in) from Financing Activities	(10,015)	(18,380)	(41,477)	18,800
Cash used in Investing Activities	(7,136)	(1,470)	(34,629)	(90,377)
Effect of foreign currency translation ¹	1,174	-	1,416	-
Net change in cash	21403	(321)	25,693	(15,835)
Select cash flow data				
Capital expenditures	(7,563)	(1,263)	(14,725)	(5,128)
Total cash outflow for leases	(8,542)	(7,454)	(25,316)	(21,927)

¹ Comprises the effect of differences in exchange rates for U.S. dollar opening balance sheet cash balances on January 1, 2022 and September 30, 2022 for Boyle Transportation and Skelton USA.

Cash Flow Generated From Operating Activities

Cash flow generated from operating activities for Q3 2022 and YTD 2022 totaled \$37.4 million and \$100.4 million, respectively, compared with \$19.5 million and \$55.7 million for Q3 2021 and YTD 2021, respectively. The increase in cash flows generated from operating activities relates principally to profitable business growth, including profitable growth from acquisitions, reflected in the 55.5% increase in YTD 2022 EBITDA and normal fluctuations in trade accounts receivable and trade accounts payable.

Cash Flow (Used In) Generated From Financing Activities

Cash flow used in financing activities for Q3 2022 and YTD 2022 totaled \$10.0 million and \$41.5 million, respectively, compared with \$18.4 million for Q3 2021 and cash flow generated from financing activities of \$18.8 million for YTD 2021. The significant cash generated from financing activities in YTD 2021 was primarily attributable to draws on our Credit Facilities in connection with the acquisitions of Skelton and 49% of Skelton USA on March 1, 2021. On March 1, 2022 we made a \$12.0 million draw on our Revolving Credit Facility in connection with the acquisition of LSU. In YTD 2022 we repaid \$23.0 million on our Revolving Credit Facility, compared with \$30.0 million repaid in YTD 2021. The remaining cash flows used in financing activities in Q3 2022, YTD 2022, Q3 2021 and YTD 2021 relate principally to ordinary course repayments of lease liabilities. In Q3 2022 and Q1 2022 we increased our quarterly dividend to \$0.07 from \$0.06 and to \$0.06 from \$0.05 per Subordinate Voting Share and Multiple Voting Share, respectively.

Cash Flow Used In Investing Activities

Cash flow used in investing activities for Q3 2022 and YTD 2022 totaled \$7.1 million and \$34.6 million, respectively, compared with cash flow used in investing activities of \$1.5 million and \$90.4 million, respectively, for Q3 2021 and YTD 2021. These amounts are primarily attributable to our acquisitions of LSU in Q1 2022 and Skelton and 49% of Skelton USA in Q1 2021, which comprised \$21.8 million and \$76.6 million, net of cash acquired, respectively. The remaining amounts comprised normal course expenditures on property, plant and equipment and intangible assets.

Contractual Obligations

As at September 30, 2022, we had the following contractual commitments:

- Outstanding letters of guarantee in the amount of \$0.4 million (September 30, 2021 – \$0.3 million);
- Commitments relating to the leasing of fleet equipment, ranging from 72 to 84 months, beginning upon delivery to us of the equipment in Fiscal 2022, for total lease commitments of \$5.6 million (September 30, 2021 – \$10.0 million); and
- Commitments to purchase fleet equipment expected to be delivered during Fiscal 2022 totaling \$13.8 million (September 30, 2021 – \$nil).

Credit facilities

As at September 30, 2022, the aggregate amounts outstanding under the Credit Facilities were \$50.0 million under the Term Facility (September 30, 2021 – \$50.0 million) and \$nil under the Revolving Credit Facility (September 30, 2021 – \$20.0 million) before capitalized financing costs. The Credit Facilities will mature and be due and payable on March 1, 2025.

Leases

We lease buildings and equipment in the operation of our healthcare logistics and specialized transportation operating segments. Building lease terms range from five to 10 years, with many leases including optional extension periods. For Q3 2022, facility lease liabilities are calculated using our incremental borrowing rate of 5.14% (Q3 2021 – 3.74%). Equipment lease terms range from one to seven years. For Q3 2022, equipment lease liabilities are calculated using our incremental borrowing rate of 4.78% (Q3 2021 – 3.14%) for our specialized transportation segment and 5.04% (Q3 2021 – 2.57%) for our healthcare logistics segment.

The following table summarizes our contractual obligations as at September 30, 2022 based on undiscounted cash flows:

(\$CAD 000s)	Total	Less than 1 Year	1-5 Years	More than 5 years
Credit facilities	50,000	-	50,000	-
Lease liabilities	134,714	32,420	86,476	15,818
Equipment purchase and lease commitments	19,373	14,665	4,708	-
Other obligations	114,147	63,037	51,110	-
Total contractual obligations	318,234	110,122	192,294	15,818

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have, or are reasonably expected to have, a current or future material impact on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Seasonality

There is no significant seasonality to our business.

Financial Instruments

Financial assets

Accounts receivable are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when we become a party to the contractual provisions of the instrument.

A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. An account receivable without a significant financing component is initially measured at the transaction price.

Our financial assets are comprised of cash and cash equivalents, accounts receivable, and long-term deposits. On initial recognition, we classify these financial assets as measured at amortized cost, when both of the following conditions are met:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These financial assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been decreased.

For accounts receivable, we apply a simplified approach in calculating expected credit losses (“ECLs”). Therefore, we do not track changes in credit risk but instead recognize a loss allowance based on lifetime ECLs at each reporting date. We have established a provision matrix that is based on our historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

When an account receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss.

Financial liabilities

Our financial liabilities are comprised of accounts payable and accrued liabilities, lease liabilities, income taxes payable and amounts due from related parties. Our financial liabilities are measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on de-recognition is also recognized in profit or loss.

Foreign exchange contracts

The Company, from time to time, uses foreign exchange contracts to manage certain exposures to fluctuations in foreign exchange rates as part of its overall risk management program. Earnings impacts from derivatives used to manage a particular risk are reported as part of other comprehensive income.

There were no foreign exchange contracts in place during YTD 2022 or as at September 30, 2022.

Related Party Transactions

Intercompany balances and transactions have been eliminated in our unaudited interim condensed consolidated financial statements for the three and nine month periods ended September 30, 2022 and 2021.

During Q3 2022 and Q3 2021, we entered into transactions with related parties that were incurred in the normal course of business. Our policy is to conduct all transactions and settle all balances with related parties at market terms and conditions. All outstanding balances with these related parties are measured at amortized cost and are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties.

Certain of our operating units provide services to other operating units outside of their reportable segment. Billings for such services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the billing segment. These rates are adjusted from time to time based on market conditions. Such intersegment revenues and expenses are eliminated in our consolidated results. Michael Andlauer, our Chief Executive Officer (“CEO”), is also our Chief Operating Decision Maker (“CODM”). The CODM regularly reviews financial information at the operating segment level in order to make decisions about resources to be allocated to the segments and to assess their performance. Segment results that are reported to the CODM include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis. We evaluate performance based on the various financial measures of our two operating segments.

The amounts below are expressed in thousands of Canadian dollars, unless otherwise specified.

Andlauer Management Group Inc.

As of the date hereof, Andlauer Management Group Inc. (“AMG”) holds all of the Multiple Voting Shares of the Company (the “Multiple Voting Shares” and, together with the Subordinate Voting Shares, the “Shares”) and 10,200 Subordinate Voting Shares, representing approximately 56.4% of the issued and outstanding Shares and 83.8% of the voting power attached to all of the Shares. AMG is owned and controlled by Michael Andlauer, our CEO and a director of the Company.

We undertake a limited amount of administrative shared services for AMG. We expect to continue to incur and recover such costs in connection with AMG. For YTD 2022, we charged AMG \$9 (YTD 2021 – \$62) for recovery of shared services costs.

Andlauer Properties and Leasing Inc.

Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and logistics and transportation equipment to us. We also lease facilities and logistics and transportation equipment from arm’s length providers. During YTD 2022, we paid \$1,749 (YTD 2021 - \$1,713) for leases of logistics and transportation equipment; and \$1,340 (YTD 2021 - \$1,328) for leases of facilities from APLI. The specific facilities that we lease from APLI are located at: 881 Bell Blvd. W, Belleville, Ontario; 18 Sandbourne Dr., Pontypool, Ontario; 80 – 14th Avenue, Hanover, Ontario; 465 Ofield Road South, Dundas, Ontario; 605 Max Brose Drive, London, Ontario; and 5480 61 Avenue SE, Calgary, Alberta. We expect to continue leasing properties and equipment from APLI. For YTD 2022, we charged APLI \$15 (YTD 2021 - \$14) for recovery of shared services costs.

9143-5271 Québec Inc.

9143-5271 Québec Inc. is a subsidiary of AMG and leases a facility located at 655 Desserte E. Hwy 13, Laval, Québec to AHG. We also lease facilities from arm’s length providers. During YTD 2022, we paid \$1,149 (YTD 2021 - \$1,149) for this building. We expect to continue leasing this property. For YTD 2022, we charged 9143-5271 Québec Inc. \$24 (YTD 2021 - \$23) for recovery of shared services costs.

Ready Staffing Solutions Inc.

Ready Staffing Solutions Inc. (“RSS”), a company owned by Mr. Andlauer’s spouse, provides us with temporary agency employee services – providing hourly dock labour for our handling operations, principally in the Greater Toronto Area. We also purchase temporary agency employee services from arm’s length providers. During YTD 2022, we expensed \$4,799 (YTD 2021 - \$3,492) for purchases of temporary agency employee services from RSS. We expect to continue purchasing temporary agency services from RSS.

1708998 Ontario Limited (Medical Courier Services)

Medical Courier Services (“MCS”) is a subsidiary owned 80% by AMG and provides transportation services to us, providing extended reach for shipments where we do not have our own facilities or equipment. During YTD 2022, we expensed \$104 (YTD 2021 - \$128) for deliveries subcontracted to MCS. We expect to continue subcontracting deliveries to MCS. Similarly, in YTD 2022 we invoiced MCS for \$132 (YTD 2021 - \$282) for transportation services provided to MCS. For YTD 2022, we charged MCS \$9 (YTD 2021 - \$10) for recovery of shared services costs.

Med Express Ltd.

Med Express Ltd. (“MEL”) is a subsidiary owned 100% by AMG. MEL provides transportation services to AHG, providing extended reach for shipments where we do not have our own facilities or equipment. We purchased \$27 in services during YTD 2022 (YTD 2021 - \$5). We expect to continue to subcontract deliveries to MEL from time to time.

D.C. Racking & Maintenance Inc. and Logiserv Inc.

D.C. Racking & Maintenance Inc. (“DCR”) and Logiserv Inc. (“Logiserv”) are owned by Cameron Joyce, an AHG director. DCR provides warehouse racking installation, maintenance and repairs for our healthcare logistics segment. Logiserv provides us with warehouse racking and racking components as well as warehouse racking installation, maintenance and repairs. We also purchase warehouse racking installation, maintenance and repairs, and warehouse racking and racking components from arm’s length providers. During YTD 2022, we purchased \$47 (YTD 2021 - \$nil) of warehouse racking and racking components from Logiserv. During YTD 2022, we expensed \$14 (YTD 2021 - \$18) for warehouse racking installation, maintenance and repair services provided by DCR and Logiserv. We expect to continue to purchase warehouse racking installation, maintenance and repair services from DCR and Logiserv.

C-GHBS Inc.

C-GHBS Inc. (“C-GHBS”) is a subsidiary of AMG and provides air travel services to us. We also purchase air travel services from arm’s length providers. During YTD 2022, we purchased \$72 (YTD 2021 - \$53) from C-GHBS. We expect to continue to purchase air travel services from C-GHBS.

Skelton Truck Lines Inc.

Skelton Truck Lines Inc. (“SKINC”) is a wholly-owned subsidiary of Skelton USA. SKINC provides specialized 2-8°C transportation services to Skelton USA in the United States, and Skelton provides specialized 2-8°C transportation services to SKINC in Canada. For the period from March 1, 2021 to September 30, 2021, AHG purchased \$300 of transportation services from SKINC and invoiced \$1,086 to SKINC. Effective November 1, 2021, we acquired the remaining 51% interest in Skelton USA, at which time SKINC became a wholly-owned subsidiary of the Company.

Key Management Personnel

Our key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include our CEO, the other four named executive officers comprising key management and the board of directors.

During YTD 2022, we recorded \$3,406 (YTD 2021 – \$3,449) related to key management personnel salaries and benefits, share-based compensation, and director fees.

Due from/to related parties

The charts below summarize amounts due to or from related parties.

(\$CAD 000s)	As at September 30,	
	2022	2021
Accounts receivable		
Andlauer Properties and Leasing Inc.	13	63
1708998 Ontario Limited (Medical Courier Services)	31	55
Trade receivables due from related parties	44	118
Due from related parties		
Skelton USA Inc.	-	1,997
Skelton Truck Lines, Inc.	-	499
Andlauer Management Group Inc.	54	5
Due from related parties	54	2,501
Total due from related parties	98	2,619
Accounts payable and accrued liabilities		
Ready Staffing Solutions Inc.	483	301
1708998 Ontario Limited (Medical Courier Services)	-	24
Andlauer Properties and Leasing Inc.	75	36
9143-5271 Quebec Inc.	-	12
Andlauer Management Group Inc.	-	1
Logiserv Inc.	-	13
C-GHBS Inc.	-	60
Trade payables due to related parties	558	447
Due to related parties		
Andlauer Properties and Leasing Inc.	123	126
Skelton Truck Lines, Inc.	-	154
Due to related parties	123	280
Total due to related parties	681	727

Critical Accounting Judgements and Estimates

The preparation of our consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions about future events. These estimates and the underlying assumptions affect the reported amounts of assets and liabilities, the disclosures about contingent assets and liabilities, and the reported amounts of revenues and expenses and apply equally to both our healthcare logistics segment and our specialized transportation segment. Such estimates include the expected credit losses on accounts receivable, the useful life of long-lived assets, our incremental borrowing rate, valuation of property, plant and equipment, valuation of goodwill and intangible assets, the measurement of identified assets and liabilities acquired in business combinations, share-based compensation arrangements, the provision for income taxes and other provisions and contingencies. These estimates and assumptions are based on management's best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. Management adjusts such estimates

and assumptions when facts and circumstances dictate. Actual results could differ from these estimates. Changes in those estimates and assumptions resulting from changes in the economic environment will be reflected in the consolidated financial statements of future periods. Information about critical judgments, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year have been described in our consolidated financial statements for the years ended December 31, 2021 and 2020. Key estimates and assumptions remain consistent with those disclosed in our consolidated financial statements.

Significant New Accounting Standards

Adopted During the Period

There were no new standards that became effective for periods beginning on or after January 1, 2022 that have a material impact on our unaudited interim condensed consolidated financial statements for YTD 2022.

To be Adopted in Future Periods

The following new standards and amendments to standards are not yet effective for the year ended December 31, 2022, and have not been applied in preparing the unaudited interim condensed consolidated financial statements for YTD 2022:

Amendments to IAS 1 – Classification of Liabilities as Current or Non-current

On January 23, 2020, the IASB issued amendments to IAS 1 – Presentation of Financial Statements, to clarify the classification of liabilities as current or non-current. The amendments are effective for annual periods beginning on or after January 1, 2023. Early adoption is permitted. For the purposes of non-current classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must have substance and exist at the end of the reporting period. The extent of the impact of adoption of the amendments has not yet been determined.

Accounting Classifications and Fair Values

Our financial instruments consist of cash and cash equivalents, accounts receivable, deposits, and accounts payable and accrued liabilities. We believe that the carrying amount of each of these items is a reasonable approximation of fair value.

Risk Factors

For a detailed description of risk factors associated with the Company, refer to the “Risk Factors” section of our AIF, which is available on the Company’s profile on SEDAR at www.sedar.com.

COVID-19

While our business has not been materially and adversely affected by the COVID-19 pandemic to date, the extent to which COVID-19 (including variant strains and mutations) and its effect on the economy will impact our business in the future remains highly uncertain and may lead to adverse changes in our cash flows, working capital levels, debt balances, operating results and financial position in the future. The situation is dynamic and the ultimate duration and magnitude of the impact on the economy and our business is not known at this time. Our pandemic management response team will continue to meet regularly as needed to review procedures, service levels, news, and Health Canada updates to address any challenges as they arise. At this

time, we do not believe there is any immediate risk of significant disruption to our services. In the event of a future significant disruption to our service, we will work closely with our clients, suppliers and regulatory authorities to prioritize the supply and delivery of essential medications and supplies. We continue to closely monitor this situation and we will provide appropriate updates in a timely manner.

In addition to the other risks that we face, which are detailed in the AIF under the heading “Risk Factors”, we have exposure, through our financial assets and liabilities, to the following risks from our use of financial instruments: credit risk, liquidity risk, interest rate risk, and currency risk. Senior management monitors risk levels and reviews risk management activities as they determine to be necessary.

Credit Risk

We are exposed to credit risk in the event of non-performance by counterparties in connection with our financial assets, namely cash and cash equivalents, accounts receivable and long-term deposits. We do not typically obtain collateral or other security to support the accounts receivable subject to credit risk but mitigate this risk by performing credit check procedures for new clients and monitoring credit limits for existing clients. Thereby, we deal only with what management believes to be financially sound counterparties and, accordingly, do not anticipate significant loss for non-performance.

The maximum exposure to credit risk for cash and cash equivalents, accounts receivable and long-term deposits approximate the amount recorded on the consolidated balance sheets.

Liquidity Risk

Liquidity risk is the risk that we will encounter difficulty in meeting the obligations associated with our financial liabilities that are settled by delivering cash or another financial asset. Our approach to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to our reputation.

Our exposure to liquidity risk is dependent on the collection of accounts receivable, or raising of funds to meet commitments and sustain operations. We control liquidity risk by management of working capital, cash flows and the availability of borrowing facilities.

We have entered into Credit Facilities with affiliates of RBC, CIBC, and The Bank of Nova Scotia, comprised of a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As at September 30, 2022, the aggregate amounts outstanding under the Credit Facilities were \$50.0 million under the Term Facility and \$nil under the Revolving Credit Facility before capitalized financing costs. As of the date of this MD&A, this accordion feature remains uncommitted.

Our accounts payable and accrued liabilities are due and payable in the short-term.

Interest Rate Risk

We have a Revolving Credit Facility and Term Facility that each bear interest at a floating rate subject to fluctuations in interest rates. Changes in interest rates can cause fluctuations in interest payments and cash flows. We do not use derivative financial instruments to mitigate the effect of this risk. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. At September 30, 2022, the Credit Facilities comprise bankers' acceptances drawn at an interest rate of 5.2%. Although interest rates have increased during YTD 2022 there has been no significant impact on our financial condition or results of operations. We expect further increases in interest rates in the near term as the Governing Council of the Bank of Canada continues to target 2-3% inflation.

Currency Risk

We enter into foreign currency purchase and sale transactions and have assets and liabilities that are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. We use derivative instruments to reduce our exposure to foreign currency risk only where appropriate, such as in connection with the Boyle Transportation acquisition.

Outstanding Share Data

Our authorized share capital consists of an unlimited number of Subordinate Voting Shares, an unlimited number of Multiple Voting Shares and an unlimited number of preferred shares, issuable in series. As at November 8, 2022, there were 18,257,283 Subordinate Voting Shares issued and outstanding, 23,600,000 Multiple Voting Shares issued and outstanding (each of which is convertible into Subordinate Voting Shares on a one-for-one basis), and no preferred shares issued and outstanding. In addition, as at such date we had 1,155,000 options, each of which can be exercised or settled for one Subordinate Voting Share and 47,378 Deferred Share Units issued and outstanding under our omnibus incentive plan. As of the date hereof, AMG holds all of the Multiple Voting Shares and 10,200 of the Subordinate Voting Shares, representing approximately 56.4% of the issued and outstanding Shares and 83.8% of the voting power attached to all of the Shares.

Subject to financial results, capital requirements, available cash flow, corporate law requirements and any other factors that our board of directors may consider relevant, we expect to declare a quarterly dividend on the Subordinate Voting Shares and Multiple Voting Shares equal to approximately \$0.07 per share on an ongoing basis. Our Q3 2022 dividend, in the amount of \$0.07 per Share, was paid on October 17, 2022 for the period beginning on July 1, 2022 and ending on September 30, 2022, to shareholders of record as at September 30, 2022. Dividends are declared and paid in arrears. The amount and timing of the payment of any dividends are not guaranteed and are subject to the discretion of our board of directors.

Disclosure Controls and Procedures and Internal Controls Over Financial Reporting

In compliance with the provisions of National Instrument 52-109 – *Certification of Disclosure in Issuers' Annual and Interim Filings*, we have filed certificates signed by our CEO and by our Chief Financial Officer ("CFO") that, among other things, report on:

- their responsibility for establishing and maintaining disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR") for the Company; and
- the design and effectiveness of DC&P and the design and effectiveness of ICFR.

Management, including our CEO and CFO, does not expect that the disclosure controls or internal controls over financial reporting of the Company will prevent or detect all errors and all fraud or will be effective under all potential future conditions. A control system is subject to inherent limitations and, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems objectives will be met.

Further, the design of a control system must reflect that there are resource constraints, and the benefits of controls must be considered relative to their costs. Inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by individual acts of some persons, by collusion of two or more people or by management override of the controls. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The design of any control system is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential conditions. Projections of any evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Disclosure Controls and Procedures

The CEO and the CFO, have designed DC&P, or have caused them to be designed under their supervision, in order to provide reasonable assurance that:

- material information relating to AHG is made known to the CEO and CFO by others, particularly during the period in which the interim and annual filings are being prepared; and
- information required to be disclosed by AHG in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation.

Internal Controls Over Financial Reporting

The CEO and CFO have also designed ICFR, or have caused them to be designed under their supervision, in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

The control framework used to design our ICFR is based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) on Internal Control – Integrated Framework (2013 framework).

Changes in Internal Controls Over Financial Reporting

No changes were made to our ICFR during Q3 2022 that have materially affected, or are reasonably likely to materially affect, our ICFR.

Limitation on Scope of Design

The scope of design of DC&P and ICFR excludes controls, policies and procedures related to LSU, which we acquired on March 1, 2022. LSU recorded approximately \$18.9 million of revenue and approximately \$1.2 million of net income for YTD 2022. Summary financial information about LSU has been consolidated in our unaudited interim condensed consolidated financial statements.

We anticipate that the design of DC&P and ICFR related to LSU will be completed prior to December 31, 2022, at which time LSU will be integrated with our existing healthcare logistics segment's control environment.

We completed the design of DC&P and ICFR related to Skelton USA and Boyle Transportation in Q3 2022 and such businesses are now integrated with our existing specialized transportation segment's control environment.

Additional Information

Additional information about AHG, including our AIF, can be found on our profile on SEDAR at www.sedar.com or on our website at www.andlauerhealthcare.com.



Unaudited Interim Condensed Consolidated
Financial Statements of

**ANDLAUER HEALTHCARE
GROUP INC.**

For the three and nine months ended September 30, 2022 and 2021

Andlauer Healthcare Group Inc.

Consolidated Balance Sheets

As at September 30, 2022 and December 31, 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

		September 30, 2022	December 31, 2021
Assets	Note		
Current assets			
Cash and cash equivalents		\$ 50,683	\$ 24,990
Trade and other receivables		98,987	90,093
Inventories		3,268	2,331
Prepaid expenses and other		6,132	4,656
Due from related parties	17	54	108
		<u>159,124</u>	<u>122,178</u>
Non-current assets			
Long-term deposits and other		990	847
Property, plant and equipment	5	174,882	178,112
Goodwill and intangible assets	6	366,930	335,200
Deferred income taxes	13	6,998	7,832
		<u></u>	<u></u>
Total Assets		\$ 708,924	\$ 644,169
Liabilities and Equity			
Current liabilities			
Revolving credit facility	7	\$ -	\$ 11,000
Accounts payable and accrued liabilities		43,562	39,404
Current portion of lease liabilities	14	27,279	26,446
Income taxes payable		19,475	13,679
		<u>90,316</u>	<u>90,529</u>
Long-term liabilities			
Lease liabilities	14	91,469	100,517
Deferred income taxes	13	50,987	50,430
Due to related parties	17	123	1,286
Term facility	7	49,489	49,288
		<u>282,384</u>	<u>292,050</u>
Total Liabilities		282,384	292,050
Equity			
Common share capital	9	727,543	719,936
Contributed surplus	11	5,764	4,967
Accumulated other comprehensive income		22,414	4,899
Merger reserve	2	(488,916)	(488,916)
Retained earnings		159,735	111,233
		<u>426,540</u>	<u>352,119</u>
Commitments and contingencies	16		
Total Liabilities and Equity		\$ 708,924	\$ 644,169

See accompanying notes to the unaudited interim condensed consolidated financial statements.

On behalf of the Board:

"Peter Jelley"
Director

"Thomas G. Wellner"
Director

Andlauer Healthcare Group Inc.

Consolidated Statements of Income and Comprehensive Income

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Note	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Revenue	12	\$ 164,898	\$ 104,199	\$ 482,651	\$ 307,090
Operating Expenses					
Cost of transportation and services		81,034	47,501	236,508	136,076
Direct operating expenses		28,262	21,393	81,291	63,582
Selling, general and administrative expenses		11,294	8,259	34,676	26,148
Depreciation and amortization		16,448	10,250	47,997	29,033
		<u>137,038</u>	<u>87,403</u>	<u>400,472</u>	<u>254,839</u>
Operating Income		27,860	16,796	82,179	52,251
Share of profit of equity-accounted investee, net of tax	4	-	1,004	-	2,098
Interest expense	15	(1,746)	(1,570)	(4,991)	(4,654)
Interest income		86	25	203	166
Other income (expenses)		(236)	(24)	(391)	104
		<u>25,964</u>	<u>16,231</u>	<u>77,000</u>	<u>49,965</u>
Income before income taxes		25,964	16,231	77,000	49,965
Current income tax expense	13	7,373	4,609	24,375	14,530
Deferred income tax recovery	13	(404)	(566)	(3,826)	(1,415)
		<u>6,969</u>	<u>4,043</u>	<u>20,549</u>	<u>13,115</u>
Net income		\$ 18,995	\$ 12,188	\$ 56,451	\$ 36,850
Net earnings per share					
Basic earnings per share	10	\$ 0.45	\$ 0.32	\$ 1.35	\$ 0.96
Diluted earnings per share	10	\$ 0.44	\$ 0.31	\$ 1.32	\$ 0.94
Other comprehensive income					
Net income		\$ 18,995	\$ 12,188	\$ 56,451	\$ 36,850
Foreign currency translation adjustment		13,907	-	17,515	-
Other comprehensive income for the period		<u>13,907</u>	<u>-</u>	<u>17,515</u>	<u>-</u>
Total comprehensive income for the period		\$ 32,902	\$ 12,188	\$ 73,966	\$ 36,850

See accompanying notes to the unaudited interim condensed consolidated financial statements.

Andlauer Healthcare Group Inc.

Consolidated Statements of Changes in Equity

For the nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Number of shares (thousands) (note 9)	Share capital (note 9)	Accumulated other compre- hensive income	Merger reserve (note 2)	Contributed surplus (note 11)	Retained earnings	Total equity
Balance at December 31, 2021	41,669	\$ 719,936	\$ 4,899	\$ (488,916)	\$ 4,967	\$ 111,233	\$ 352,119
Net income and comprehensive income for the period	-	-	17,515	-	-	56,451	73,966
Shares issued in connection with business combinations (note 4)	155	7,500	-	-	-	-	7,500
Transaction costs, net of tax (notes 4, 9, 13)	-	(63)	-	-	-	-	(63)
Share-based compensation (note 11)	33	170	-	-	797	-	967
Dividends (note 9)	-	-	-	-	-	(7,949)	(7,949)
Balance at September 30, 2022	41,857	\$ 727,543	\$ 22,414	\$ (488,916)	\$ 5,764	\$ 159,735	\$ 426,540
Balance at December 31, 2020	37,603	\$ 549,662	\$ -	\$ (488,916)	\$ 4,448	\$ 29,133	\$ 94,327
Net income and comprehensive income for the period	-	-	-	-	-	36,850	36,850
Shares issued in connection with business combination (note 4)	758	25,000	-	-	-	-	25,000
Transaction costs (note 4)	-	(78)	-	-	-	-	(78)
Share-based compensation	119	1,030	-	-	788	-	1,818
Dividends (note 9)	-	-	-	-	-	(5,771)	(5,771)
Balance at September 30, 2021	38,480	\$ 575,614	\$ -	\$ (488,916)	\$ 5,236	\$ 60,212	\$ 152,146

See accompanying notes to the unaudited interim condensed consolidated financial statements.

Andlauer Healthcare Group Inc.
Consolidated Statements of Cash Flow
For the nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Note	September 30, 2022	September 30, 2021
Operating activities			
Net income for the period		\$ 56,451	\$ 36,850
Changes not involving cash:			
Depreciation and amortization		47,997	29,033
Amortization of capitalized financing costs	7	201	175
Share-based compensation	11	967	1,392
Share of profit of equity-accounted investee, net of tax	4	-	(2,098)
Deferred income tax recovery	13	(3,826)	(1,415)
Loss on disposal of property, plant and equipment		20	72
Net gain on derecognition of right-of-use assets	14	-	(142)
		<u>101,810</u>	<u>63,867</u>
Changes in non-cash operating working capital:			
Trade and other receivables		(3,120)	(12,915)
Inventories		(256)	(89)
Accounts payable and accrued liabilities		2,005	3,648
Income taxes payable		1,282	2,197
Net change in other operating working capital balances		<u>(1,338)</u>	<u>(966)</u>
Cash flows from operating activities		<u>100,383</u>	<u>55,742</u>
Financing activities			
Dividends	9	(7,949)	(5,771)
Principal repayments on lease liabilities	14	(21,688)	(18,316)
Net change in related party balances		(777)	(1,840)
Proceeds from revolving credit facility	7	12,000	50,000
Proceeds from term facility	7	-	25,000
Repayment of revolving credit facility	7	(23,000)	(30,000)
Net financing costs on credit facilities	7	-	(621)
Proceeds from issuance of share capital		-	426
Transaction costs recorded in share capital	9	(63)	(78)
Cash flows (used in) from financing activities		<u>(41,477)</u>	<u>18,800</u>
Investing activities			
Purchase of property, plant and equipment		(14,725)	(5,128)
Proceeds on disposal of property, plant and equipment		1,021	33
Purchase of intangible assets	6	(1,607)	(990)
Acquisition of equity accounted investee	4	-	(7,648)
Business combinations, net of cash acquired	4	(19,318)	(76,644)
Cash flows used in investing activities		<u>(34,629)</u>	<u>(90,377)</u>
Net increase (decrease) in cash and cash equivalents		24,277	(15,835)
Effect of foreign currency translation on cash and cash equivalents		1,416	-
Cash and cash equivalents, beginning of period		<u>24,990</u>	<u>30,148</u>
Cash and cash equivalents, end of period		<u>\$ 50,683</u>	<u>\$ 14,313</u>

See accompanying notes to the unaudited interim condensed consolidated financial statements.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

1. Reporting entity

Andlauer Healthcare Group Inc. ("AHG", or the "Company") was incorporated under the Ontario Business Corporations Act with its head office located at 100 Vaughan Valley Blvd. in Woodbridge, Ontario. AHG's subordinate voting shares are listed on the Toronto Stock Exchange under the stock symbol "AND". AHG specializes in third party logistics and transportation solutions for the healthcare sector in Canada and the United States.

In addition to the shares issued to the public, Andlauer Management Group Inc. ("AMG") holds 23.6 million multiple voting shares and 10,200 subordinate voting shares of AHG, representing approximately 56.4% of the issued and outstanding shares and 83.8% of the voting power attached to all of the shares. AMG is owned and controlled by Michael Andlauer, Chief Executive Officer, Chief Operating Decision Maker ("CODM"), and a director of AHG.

2. Basis of presentation

a) Statement of compliance

These unaudited interim condensed consolidated financial statements ("consolidated financial statements") have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). Under International Financial Reporting Standards ("IFRS"), additional disclosures are required in the annual financial statements and therefore, these consolidated financial statements and accompanying notes should be read in conjunction with the notes to the Company's audited consolidated financial statements for the years ended December 31, 2021 and 2020.

These consolidated financial statements have been prepared using consistent accounting policies and methods used in the preparation of the Company's annual audited consolidated financial statements.

These consolidated financial statements were authorized for issue by the Board of Directors effective November 8, 2022.

b) Basis of measurement

These consolidated financial statements were prepared on a going concern basis under the historical cost method except for share based compensation and business combinations, which were recorded at fair value.

Common control transaction

These consolidated financial statements comprise the results of AHG and Associated Logistics Solutions Inc., Credo Canada Systems Inc., 2186940 Ontario Inc., Skelton Canada Inc., and their respective subsidiaries. Prior to the Company's initial public offering ("IPO") on December 11, 2019, certain of AHG's subsidiaries (Associated Logistics Solutions Inc., Credo Canada Systems Inc., 2186940 Ontario Inc. and their respective subsidiaries at that time – collectively, the "AHG Entities") were owned 100% by AMG. Pursuant to a share purchase agreement between AHG and AMG, and in connection with a corporate reorganization immediately prior to the IPO, AHG acquired a 100% ownership interest in the AHG Entities based on the value of consideration of \$577,625. Total net parent investment immediately prior to the IPO was \$88,709. A merger reserve of \$488,916 is recorded to reflect the difference in carrying value of the net assets acquired and the consideration paid since AHG and the AHG Entities were all related parties under common control of AMG at the time of the acquisition. Business combinations involving entities under common control are outside the scope of IFRS 3 Business Combinations. AHG accounted for this common control transaction using book value accounting, based on the book values recognized in the financial statements of the underlying entities.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

2. Basis of presentation (continued)

c) Basis of consolidation

(i) Business combinations

The Company accounts for acquired businesses using the acquisition method of accounting by recording assets acquired and liabilities assumed at their respective fair values. The Company measures goodwill as the fair value of the consideration transferred including the fair value of liabilities resulting from contingent consideration arrangements, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured at fair value as of the acquisition date.

Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.

(ii) Subsidiaries

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The Company controls an entity when it is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of subsidiaries are aligned with the policies adopted by the Company.

(iii) Transactions eliminated on consolidation

Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the consolidated financial statements.

d) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented in Canadian dollars has been rounded to the nearest thousand. The functional currency of Canadian operations is the Canadian dollar and the functional currency of U.S. operations is the U.S. dollar.

e) Judgments and estimates

Preparing the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. In preparing these consolidated financial statements, significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended December 31, 2021.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

3. Segment reporting

The Company is organized into operating segments, which aggregate into two reportable segments: Specialized Transportation and Healthcare Logistics. The operating segments are managed independently as they require different technology and capital resources. For each of the operating segments, the Company's CODM reviews internal management reports, evaluating the metrics as summarized in the tables that follow.

The Company evaluates performance based on the various financial measures of its operating segments. Performance is measured based on segment income or loss before tax. This measure is included in the internal management reports that are reviewed by the Company's CEO and refers to "Income before income taxes" in the consolidated statements of income and comprehensive income. Segment income or loss before tax is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within the same industries.

The following table identifies selected financial data as at September 30, 2022 and 2021 and for the three months then ended:

	Specialized Transportation	Healthcare Logistics	Corporate	Eliminations	Total
As at September 30, 2022 and for the three months then ended					
Revenue	\$ 130,036	\$ 48,017	\$ 1,113	\$ (14,268)	\$ 164,898
Segment income before tax	19,608	6,327	29	-	25,964
Interest income	(795)	(22)	903	-	86
Interest expense	(921)	(557)	(268)	-	(1,746)
Depreciation and amortization	(12,742)	(3,706)	-	-	(16,448)
Segment net income	14,410	4,616	(31)	-	18,995
Segment total assets	554,389	175,229	736,520	(757,214)	708,924
Additions of ROU assets	3,296	-	-	-	3,296
Capital expenditures	7,097	466	-	-	7,563
Segment total liabilities	248,676	92,951	30,464	(89,707)	282,384
As at September 30, 2021 and for the three months then ended					
Revenue	\$ 80,253	\$ 33,457	\$ 945	\$ (10,456)	\$ 104,199
Segment income before tax	12,817	3,598	(184)	-	16,231
Interest income	(789)	15	799	-	25
Interest expense	(903)	(550)	(117)	-	(1,570)
Depreciation and amortization	(7,234)	(3,016)	-	-	(10,250)
Segment net income	9,751	2,654	(217)	-	12,188
Segment total assets	272,161	130,702	596,580	(603,444)	395,999
Additions of ROU assets	1,955	107	-	-	2,062
Capital expenditures	1,046	217	-	-	1,263
Segment total liabilities	190,083	70,157	31,690	(48,077)	243,853

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

3. Segment reporting (continued)

The following table identifies selected financial data as at September 30, 2022 and 2021 and for the nine months then ended:

	Specialized Transportation	Healthcare Logistics	Corporate	Eliminations	Total
As at September 30, 2022 and for the nine months then ended					
Revenue	\$ 385,554	\$ 135,029	\$ 3,353	\$ (41,285)	\$ 482,651
Segment income before tax	61,025	16,252	(277)	-	77,000
Interest income	(2,341)	(67)	2,611	-	203
Interest expense	(2,721)	(1,611)	(659)	-	(4,991)
Depreciation and amortization	(37,338)	(10,659)	-	-	(47,997)
Segment net income	44,935	11,884	(368)	-	56,451
Segment total assets	554,389	175,229	736,520	(757,214)	708,924
Additions of ROU assets	9,437	198	-	-	9,635
Additions of property, plant and equipment through business combinations ¹	-	5,159	-	-	5,159
Capital expenditures	13,267	1,458	-	-	14,725
Segment total liabilities	248,676	92,951	30,464	(89,707)	282,384
As at September 30, 2021 and for the nine months then ended					
Revenue	\$ 233,770	\$ 101,455	\$ 2,835	\$ (30,970)	\$ 307,090
Segment income before tax	39,181	11,787	(1,003)	-	49,965
Interest income	(2,347)	108	2,405	-	166
Interest expense	(2,668)	(1,634)	(352)	-	(4,654)
Depreciation and amortization	(19,996)	(9,037)	-	-	(29,033)
Segment net income	29,234	8,688	(1,072)	-	36,850
Segment total assets	272,161	130,702	596,580	(603,444)	395,999
Additions of ROU assets	19,634	11,010	-	-	30,644
Additions of property, plant and equipment through business combinations ¹	27,840	-	-	-	27,840
Capital expenditures	19,984	1,949	-	-	21,933
Segment total liabilities	190,083	70,157	31,690	(48,077)	243,853

¹ Includes \$3,798 for the period ended September 30, 2022 (2021 - \$11,035) of ROU assets acquired through business combinations

The Company's Healthcare Logistics segment purchases transportation services from its Specialized Transportation segment. Fees for these services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the Specialized Transportation segment. Rates are adjusted from time to time based on market conditions. The Company also charges fees for services and costs incurred from its corporate office to subsidiaries. Intersegment revenues and expenses and related intersegment payables and receivables are eliminated in the Company's consolidated results.

The Company does not have any customers that individually represent more than 10% of revenue for the periods ended September 30, 2022 and 2021.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

4. Business combinations

On March 1, 2022, the Company acquired all of the issued and outstanding shares of Logistics Support Unit (LSU) Inc. ("LSU"), a leading third-party logistics provider offering specialty pharmacy, warehousing, distribution and order management services throughout Canada to national and international companies, as well as government clients in the pharmaceutical, medical and biotechnology sectors, for \$26,747, the estimated fair value of the business acquired. The acquisition was financed through a combination of cash on hand, drawing \$12,000 on the credit facilities and by issuing 154,639 subordinate voting shares totaling \$7,500 to the shareholder of LSU.

On March 1, 2021, the Company acquired all of the issued and outstanding shares of Skelton Canada Inc. ("Skelton"), a leading transportation partner to the Canadian pharmaceutical and biologics industry for \$107,306, the estimated fair value of the business acquired. The acquisition was financed through a combination of cash on hand, drawing \$75,000 on the credit facilities and by issuing 757,576 subordinate voting shares totaling \$25,000 to the shareholders of Skelton. As part of the same transaction, the Company acquired a 49% interest in Skelton USA Inc. ("Skelton USA"), whose wholly-owned subsidiary, Skelton Truck Lines, Inc., operates domestically in the United States, for cash consideration of \$7,642. Management determined that it did not control Skelton USA until AHG acquired the remaining 51% of Skelton USA on November 1, 2021. Accordingly, between March 1, 2021 and September 30, 2021, the Company accounted for its investment in Skelton USA using the equity method of accounting.

Under the equity method of accounting, an equity investment is initially recorded at cost and is subsequently adjusted to reflect the investor's share of the net profit or loss of the associate. The Company's 49% share of total comprehensive income of Skelton USA for the period from March 1, 2021 to September 30, 2021 was \$2,098.

For the period from acquisition on March 1, 2022 to September 30, 2022, LSU contributed revenue of \$18,860 and net income before amortization of intangible assets acquired of \$2,173 (\$1,245 net of intangible amortization) to the Company's financial results.

For the period from acquisition on March 1, 2021 to September 30, 2021, Skelton contributed revenue of \$25,491 and net income of \$3,675 (\$1,393 net of intangible amortization) to the Company's financial results.

If the Company had acquired LSU and Skelton on January 1, 2022 and January 1, 2021 respectively, management estimates that consolidated revenue would have been approximately \$486,900 and \$315,000, respectively, and consolidated net income would have been approximately \$58,200 and \$37,500 respectively. In determining these amounts, management has assumed that the fair value adjustments that arose on the dates of acquisition would have been the same had the acquisitions occurred on January 1, 2022 and January 1, 2021 respectively.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

4. Business combination (continued)

During the nine months ended September 30, 2022, transaction costs of \$345 (September 30, 2021 – \$911) have been expensed in selling, general and administrative expenses in the consolidated statements of income and comprehensive income and \$63 (2021 – \$78), net of deferred taxes, has been charged to share capital in relation to these acquisitions.

The following table summarizes the acquisition date fair value of identifiable net assets and goodwill acquired:

Identifiable assets acquired and liabilities assumed	LSU (March 1, 2022)	Skelton (March 1, 2021)
Cash and cash equivalents	\$ (71)	\$ 5,662
Trade and other receivables	4,636	4,590
Inventories	663	451
Prepaid expenses and other	140	274
Property, plant and equipment, including ROU assets	5,159	27,840
Intangible assets	15,900	39,100
Accounts payable and accrued liabilities	(1,778)	(1,384)
Income taxes payable	(4,160)	(1,005)
Lease liabilities	(3,398)	(7,121)
Deferred tax liabilities	(2,496)	(13,990)
Total identifiable net assets	14,595	54,417
Goodwill	12,152	52,889
Final purchase consideration	\$ 26,747	\$ 107,306

Trade and other receivables comprise gross amounts due of \$4,636 (2021 - \$4,590), all of which were expected to be collectible at the acquisition dates.

When measuring the fair value of property, plant and equipment, the Company considers market prices for similar items when they are available, and depreciated replacement cost when appropriate. Depreciated replacement cost reflects adjustments for physical deterioration as well as functional and economic obsolescence.

The Company attributes value to the customer relationships maintained by LSU and Skelton, and to the brands of each acquired entity. For the nine months ended September 30, 2022, the Company recorded intangible assets of \$12,700 (2021 - \$27,900) in connection with customer relationships and \$3,200 (2021 – \$11,200) in connection with the brands of its acquisitions. The customer relationships and brands are definite life intangible assets each of which will be amortized over 10 years.

The goodwill is principally attributable to the premium of established business operations, each with a strong reputation in healthcare logistics or specialized transportation, and the synergies expected to be achieved from integrating LSU and Skelton into the Company's existing business. Goodwill arising from the Company's business combinations has been allocated to the Healthcare Logistics segment for LSU and to the Specialized Transportation segment for Skelton.

Of the goodwill acquired through the business combinations, \$4,850 (2021 – \$nil) is deductible for tax purposes.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

5. Property, plant and equipment

Reconciliation of the net carrying amounts for each class of property, plant and equipment is summarized below:

	Facilities ¹	Furniture and fixtures	Leasehold improvements	Logistics and transportation equipment ¹	Total
Cost					
Balance at December 31, 2021	\$ 155,855	\$ 8,664	\$ 21,433	\$ 154,314	\$ 340,266
Additions	2,171	254	1,415	20,520	24,360
Additions through business combinations (note 4)	2,756	-	672	1,731	5,159
Dispositions	-	(7)	(29)	(1,657)	(1,693)
Foreign currency adjustments	465	18	124	1,745	2,352
Balance at September 30, 2022	161,247	8,929	23,615	176,653	370,444
Accumulated depreciation					
Balance at December 31, 2021	\$ 66,512	\$ 6,769	\$ 11,357	\$ 77,516	\$ 162,154
Depreciation for the period	13,046	301	1,796	18,474	33,617
Dispositions	-	(3)	-	(649)	(652)
Foreign currency adjustments	52	2	7	382	443
Balance at September 30, 2022	79,610	7,069	13,160	95,273	195,562
Net carrying amounts					
At December 31, 2021	\$ 89,343	\$ 1,895	\$ 10,076	\$ 76,798	\$ 178,112
At September 30, 2022	\$ 81,637	\$ 1,860	\$ 10,455	\$ 80,930	\$ 174,882

¹ Facilities and certain logistics and transportation equipment assets are ROU assets, capitalized in accordance with IFRS 16. Refer to note 14.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

6. Goodwill and intangible assets

	Goodwill	Customer relationships	Brand	Software	Total
Cost					
Balance at December 31, 2021	\$ 176,737	\$ 147,254	\$ 37,950	\$ 7,668	\$ 369,609
Additions	-	-	-	1,607	1,607
Additions through business combinations (note 4)	12,152	12,700	3,200	-	28,052
Foreign currency adjustments	7,790	7,266	2,171	-	17,227
Balance at September 30, 2022	196,679	167,220	43,321	9,275	416,495
Accumulated amortization					
Balance at December 31, 2021	\$ -	\$ 28,193	\$ 1,376	\$ 4,840	\$ 34,409
Amortization for the period	-	10,784	3,218	378	14,380
Foreign currency adjustments	-	590	186	-	776
Balance at September 30, 2022	-	39,567	4,780	5,218	49,565
Net carrying amounts					
At December 31, 2021	\$ 176,737	\$ 119,061	\$ 36,574	\$ 2,828	\$ 335,200
At September 30, 2022	\$ 196,679	\$ 127,653	\$ 38,541	\$ 4,057	\$ 366,930

7. Credit facilities

	September 30, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Term facility	50,000	50,000
	50,000	61,000
Less: capitalized financing costs	(511)	(712)
Credit facilities	\$ 49,489	\$ 60,288

Recorded in the consolidated balance sheets as follows:

	September 30, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Term facility	49,489	49,288
Credit facilities	\$ 49,489	\$ 60,288

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

7. Credit facilities (continued)

The movement in credit facilities from December 31, 2021 is as follows:

	Credit Facilities
Balance at December 31, 2021	\$ 60,288
Changes from financing cash flows	
Issuance of borrowings – revolving credit facility	12,000
	72,288
Repayment of revolving credit facility	(23,000)
Non-cash movements	
Amortization of capitalized financing costs	201
Balance at September 30, 2022	\$ 49,489

The Company is party to credit facilities with a syndicate of lenders. On February 19, 2021, in connection with the anticipated acquisitions of Skelton and Skelton USA, the credit facilities were amended to increase the amounts available to be drawn under the revolving credit facility and the term facility each by \$25,000. The amended credit facilities comprise a revolving credit facility in the aggregate principal amount of up to \$100,000 and a term facility in the aggregate principal amount of up to \$50,000. The remaining terms and conditions of the credit facilities were unchanged, except that they will mature and be due and payable on March 1, 2025. There is no repayment schedule for either the revolving credit facility or the term facility, except at maturity; however, the Company classifies the revolving credit facility in current liabilities because of its intention to reduce drawn amounts with cash flow from operations within twelve months. Financing costs of \$621, which apply to the credit facilities in aggregate, were capitalized in the term facility in connection with the amendment.

The credit facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans, and letters of credit, in each case, plus the applicable margin in effect from time to time. At September 30, 2022, the credit facilities comprise bankers' acceptances drawn at an interest rate of 5.2% (December 31, 2021 – 1.9%).

The credit facilities are guaranteed by each of the Company's material subsidiaries and are secured by (i) a first priority lien over all personal property of the Company, subject to certain exclusions and permitted liens, (ii) charges over certain material leased real property interests, and (iii) a first ranking pledge of 100% of the securities of any subsidiary owned by the Company.

The credit facilities are subject to customary negative covenants and include financial covenants requiring the Company to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. At September 30, 2022, the Company was in compliance with all of its covenants under the credit facilities.

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense on the credit facilities for the three and nine months ended September 30, 2022 was \$489 and \$1,294 (2021 – \$362 and \$1,043 respectively).

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

8. Financial instruments and financial risk management

Accounting classifications and fair values

The Company's financial instruments consist of cash and cash equivalents, trade and other receivables, long-term deposits and other, accounts payable and accrued liabilities and its credit facilities (refer to note 7). The Company believes that the carrying amount of each of these items is a reasonable approximation of fair value given the short-term nature of the financial instruments.

As the credit facilities bear interest at a floating rate subject to fluctuations in the bank prime rate the carrying value of the debt approximates fair value.

9. Share capital

The Company is authorized to issue an unlimited number of subordinate voting common shares, an unlimited number of multiple voting common shares, and an unlimited number of preferred shares, issuable in series. The subordinate voting shares and multiple voting shares rank *pari passu* with respect to the payment of dividends, return of capital and distribution of assets in the event of liquidation, dissolution, or wind-up. Holders of multiple voting shares are entitled to four votes per multiple voting share, and holders of subordinate voting shares are entitled to one vote per subordinate voting share on all matters upon which holders of shares are entitled to vote.

As of the date hereof, all of the multiple voting shares and 10,200 subordinate voting shares are owned by AMG. The following table summarizes the number of common shares issued:

	Number of common shares (in thousands)			Share capital (in thousands of dollars)		
	Multiple voting common shares	Subordinate voting common shares	Total common shares	Multiple voting common shares	Subordinate voting common shares	Total share capital
Balance at December 31, 2021	23,600	18,069	41,669	\$ 354,000	\$ 365,936	\$ 719,936
Shares issued in connection with business combination (note 4)	-	155	155	-	7,500	7,500
Shares issued in connection with the exercise of options	-	33	33	-	170	170
Transaction costs, net of tax	-	-	-	-	(63)	(63)
Balance at September 30, 2022	23,600	18,257	41,857	\$ 354,000	\$ 373,543	\$ 727,543

Transaction costs of \$63, net of deferred taxes, have been offset against subordinate voting shares in connection with acquisitions made during the nine months ended September 30, 2022 (2021 – \$78) (note 4).

Dividends to subordinate voting and multiple voting shareholders

During the nine months ended September 30, 2022, the Company declared total dividends of \$7,949, or \$0.19 per common share (September 30, 2021 – \$5,771, or \$0.15 per common share), on subordinate voting and multiple voting shares. Included in accounts payable and accrued liabilities as at September 30, 2022 is \$2,930 (September 30, 2021 – \$1,924) for dividends paid on October 17, 2022 and October 15, 2021, to common shareholders of record on September 30, 2022 and 2021 respectively.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

10. Earnings per share

Basic earnings per share

The basic earnings per share and the weighted average number of common shares outstanding have been calculated as follows:

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
(in thousands of dollars and number of shares)				
Net income	\$ 18,995	\$ 12,188	\$ 56,451	\$ 36,850
Weighted average number of common shares	41,835	38,477	41,794	38,282
Earnings per share – basic	\$ 0.45	\$ 0.32	\$ 1.35	\$ 0.96

Diluted earnings per share

The basic earnings per share and the weighted average number of common shares outstanding after adjustment for the effects of all dilutive common shares have been calculated as follows:

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
(in thousands of dollars and number of shares)				
Net income	\$ 18,995	\$ 12,188	\$ 56,451	\$ 36,850
Weighted average number of common shares	41,835	38,477	41,794	38,282
Dilutive effects:				
Stock options	822	941	815	900
Deferred share units	44	31	42	27
Weighted average number of diluted common shares	42,701	39,449	42,651	39,209
Earnings per share – diluted	\$ 0.44	\$ 0.31	\$ 1.32	\$ 0.94

11. Share-based payment arrangements

Stock option plan (equity settled)

The Company offers a stock option plan for the benefit of certain of its employees. Each stock option entitles its holder to receive one subordinate voting common share upon exercise. The exercise price payable for each option is determined by the Board of Directors at the date of grant. The options vest in equal installments over four years and the expense is recognized following the treasury method as each installment is fair valued separately and recorded over the respective vesting periods.

On December 11, 2019 the Board of Directors approved a grant of 1.65 million options, of which 47 thousand options were exercised during the nine months ended September 30, 2022 (September 30, 2021 – 168 thousand). Of the options outstanding at September 30, 2022, a total of 635 thousand (December 31, 2021 – 667 thousand) are held by non-executive directors; 225 thousand (December 31, 2021 – 225 thousand) are held by executive officers; with the remaining 295 thousand (December 31, 2021 – 310 thousand) held by management personnel.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

11. Share-based payment arrangements (continued)

Stock option plan (equity-settled) (continued)

The table below summarizes the changes in the outstanding stock options:

	<u>Nine months ended September 30, 2022</u>		<u>Nine months ended September 30, 2021</u>	
(in thousands of options and in dollars)	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Opening balance	1,202	\$ 15.00	1,644	\$ 15.00
Exercised	(47)	15.00	(168)	15.00
Forfeited	-	-	(18)	15.00
Ending balance	1,155	\$ 15.00	1,458	\$ 15.00
Options exercisable	568	\$ 15.00	501	\$ 15.00

The Company recognized compensation expense of \$167 and \$502 for the three and nine months ended September 30, 2022 respectively (2021 – \$309 and \$925 respectively), with corresponding increases to contributed surplus in connection with the vesting of options issued at the time of the initial public offering.

Director deferred share units (“DSUs”) program (equity settled)

Each non-executive director receives at least 50% of his or her annual director retainer in DSUs. DSUs vest when granted but are not redeemable for settlement until the director ceases to be a member of the Board. The number of DSUs issued is calculated for each director as the director’s quarterly retainer divided by the volume weighted average trading price on the TSX for the five trading days prior to such issuance. For the three and nine months ended September 30, 2022, the Company recognized a compensation expense of \$155 and \$465 respectively, with corresponding increases to contributed surplus (2021 – \$155 and \$467 respectively).

The table below summarizes the changes in the outstanding DSUs:

(thousands of DSUs)	<u>September 30, 2022</u>	<u>September 30, 2021</u>
Opening balance	37	23
Granted	10	11
Closing balance	47	34

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

12. Revenue

a) Revenue streams

The Company generates revenue primarily from the provision of supply chain transportation and logistics services to its customers. The Company's contracts are typically satisfied over a short period of time. Consequently, the Company applies the practical expedient and does not disclose information related to its remaining performance obligations.

b) Disaggregation of revenue from contracts with customers

In the following table, revenue from contracts with customers is disaggregated by major products and service lines. The table also includes a reconciliation of the disaggregated revenue with the Company's reportable segments (note 3), and revenue disaggregated by primary geographical markets. All of the revenue generated in the United States comprises ground transportation revenue.

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Major products/service lines				
Logistics and distribution	\$ 42,574	\$ 28,953	\$ 117,664	\$ 85,734
Packaging solutions	5,443	4,504	17,365	15,721
Healthcare Logistics segment	48,017	33,457	135,029	101,455
Ground transportation	105,353	60,750	309,180	176,602
Air freight forwarding	7,704	6,155	26,834	19,190
Dedicated and last mile delivery	16,980	13,348	49,540	37,978
Intersegment revenue	(13,156)	(9,511)	(37,932)	(28,135)
Specialized Transportation segment	116,881	70,742	347,622	205,635
Total revenue	\$ 164,898	\$ 104,199	\$ 482,651	\$ 307,090
	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Primary geographical markets				
Canada	\$ 130,377	\$ 104,199	\$ 385,289	\$ 307,090
United States	34,521	-	97,362	-
Total revenue	\$ 164,898	\$ 104,199	\$ 482,651	\$ 307,090

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

13. Income taxes

a) Amounts recognized in profit or loss

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Current income tax expense:				
Current taxes on income for the reporting period	\$ 7,373	\$ 4,609	\$ 24,375	\$ 14,266
Current taxes relating to previous periods and other adjustments	-	-	-	264
	7,373	4,609	24,375	14,530
Deferred income tax recovery:				
Recognition of tax benefits related to loss for the period	(166)	(117)	(574)	(489)
Origination and reversal of temporary differences	(238)	(449)	(3,252)	(862)
Deferred taxes relating to previous periods and other adjustments	-	-	-	(153)
Deductible temporary differences not recognized	-	-	-	89
	(404)	(566)	(3,826)	(1,415)
Income tax expense reported to the statements of income and comprehensive income	\$ 6,969	\$ 4,043	\$ 20,549	\$ 13,115

Total cash outflow for actual taxes paid for the three and nine months ended September 30, 2022 was \$7,221 and \$22,818 respectively (2021 – \$3,625 and \$12,785 respectively).

b) Amounts recognized directly in equity

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Transaction costs (recovery), before tax	\$ -	\$ -	\$ 86	\$ 78
Tax	-	-	(23)	-
Transaction costs, net of tax	\$ -	\$ -	\$ 63	\$ 78

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

13. Income taxes (continued)

c) Reconciliation of effective tax rate

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Income before income taxes	\$ 25,964	\$ 16,231	\$ 77,000	\$ 49,965
Consolidated Canadian federal and provincial income tax rate	26.5%	26.5%	26.5%	26.5%
Income tax expense based on statutory rate	6,880	4,301	20,405	13,241
Increase (decrease) in income taxes resulting from non-deductible (non-taxable) items or other adjustments	89	(428)	144	(296)
Impact of varying statutory tax rates of subsidiaries	-	(30)	-	(30)
Deductible temporary differences not recognized	-	89	-	89
Taxes relating to previous periods and other adjustments	-	111	-	111
Total income tax expense	\$ 6,969	\$ 4,043	\$ 20,549	\$ 13,115

d) Deferred taxes

	September 30, 2022	December 31, 2021
Deferred tax assets	\$ 6,998	\$ 7,832
Deferred tax liabilities	(50,987)	(50,430)
Net deferred tax liability	\$ (43,989)	\$ (42,598)

e) Movement in deferred tax balances

	September 30, 2022	Recognized in equity	Recognized in income or loss	Acquired in business combina- tions (note 4)	Foreign currency adjustments	December 31, 2021
Plant and equipment	\$ (12,501)	\$ -	\$ 973	\$ (560)	\$ (522)	\$ (12,392)
Accounts payable and accrued liabilities	741	-	134	-	-	607
Intangibles	(41,734)	-	3,690	(2,107)	(2,331)	(40,986)
Benefit of losses carried forward	2,728	-	574	-	-	2,154
Leases	4,264	-	(764)	170	110	4,748
Transaction costs	2,513	23	(781)	-	-	3,271
Net deferred tax (liability) asset	\$ (43,989)	\$ 23	\$ 3,826	\$ (2,497)	\$ (2,743)	\$ (42,598)

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

13. Income taxes (continued)

e) Movement in deferred tax balances (continued)

	December 31, 2021	Recognized in equity	Recognized in income or loss	Acquired in business combina- tions	Foreign currency adjustments	September 30, 2021
Plant and equipment	\$ (12,392)	\$ -	574	\$ (7,019)	\$ (176)	\$ (5,771)
Accounts payable and accrued liabilities	607	-	111	-	-	496
Intangibles	(40,986)	-	855	(30,622)	(766)	(10,453)
Benefit of losses carried forward	2,154	237	125	-	-	1,792
Leases	4,748	-	(140)	1,693	42	3,153
Transaction costs	3,271	947	(45)	-	-	2,369
Net deferred tax asset (liability)	\$ (42,598)	\$ 1,184	1,480	\$ (35,948)	\$ (900)	\$ (8,414)

	September 30, 2021	Recognized in income or loss	Acquired in business combina- tions (note 4)	December 31, 2020
Plant and equipment	\$ (5,771)	\$ 796	\$ (5,515)	\$ (1,052)
Accounts payable and accrued liabilities	496	43	-	453
Intangibles	(10,453)	994	(10,362)	(1,085)
Benefit of losses carried forward	1,792	489	-	1,303
Leases	3,153	(218)	1,887	1,484
Transaction costs	2,369	(689)	-	3,058
Net deferred tax asset (liability)	\$ (8,414)	\$ 1,415	\$ (13,990)	\$ 4,161

f) Unrecognized deferred tax liabilities

As at September 30, 2022, temporary differences of \$40,390 (December 31, 2021 – \$40,390) exist in connection with wholly-owned investments in subsidiaries; and the related potential deferred tax liability of \$5,352 (December 31, 2021 – \$5,352) has not been recognized. The Company controls the dividend policies of its subsidiaries and controls the timing of payment of such dividends. Accordingly, the Company controls the timing of reversal of the related taxable temporary differences; and management is satisfied that they will not reverse in the foreseeable future.

g) Non-capital loss carryforwards

The Company recognized deferred tax assets in connection with certain losses for the current period on the basis that it will have sufficient future taxable profit.

The Company has total non-capital tax loss carry forwards of \$10,264 that begin to expire in 2039.

h) Uncertainty over income tax treatments

The calculation of current and deferred income taxes requires management to make certain judgements regarding the tax rules in jurisdictions where the Company performs activities. The Company believes that its accruals for tax liabilities are adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

14. Leases

The Company leases buildings and equipment in the operation of its Transportation and Logistics businesses. The Company is required to estimate the incremental borrowing rates used to discount lease liabilities if the interest rate implicit in the lease is not readily determined. The Company estimates its incremental borrowing rates for portfolios of leases with similar characteristics, such as similar risk profiles, same or similar types of security, and similar lease terms. Building lease terms range from 5 to 10 years. Facilities lease liabilities are calculated using the Company's incremental borrowing rate based on the specific lease commitments and term for each facility. The average incremental borrowing rate for facilities for the nine months ended September 30, 2022 is 5.14% (year ended December 31, 2021 – 3.71%). Equipment lease terms range from 1 to 7 years. Equipment lease liabilities are calculated using the operating segment's average incremental borrowing rate on an equipment lease portfolio basis for that period. The average incremental borrowing rate for equipment for the nine months ended September 30, 2022 is 4.78% for Specialized Transportation and 5.04% for Healthcare Logistics (year ended December 31, 2021 – 3.13% for Specialized Transportation; 2.66% for Healthcare Logistics).

Right-of-use assets – Facilities	As at and for the nine months ended September 30, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 89,343	\$ 71,484
Add: additions	2,171	26,144
Add: additions through business combinations	2,756	8,449
Less: derecognition	-	(1,347)
Less: depreciation	(13,046)	(15,527)
Foreign currency adjustments	413	140
Ending balance	\$ 81,637	\$ 89,343
Right-of-use assets – Logistics and transportation equipment	As at and for the nine months ended September 30, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 33,443	\$ 27,256
Add: additions	7,464	7,431
Add: additions through business combinations	1,042	9,349
Less: depreciation	(8,565)	(10,622)
Foreign currency adjustments	88	29
Ending balance	\$ 33,472	\$ 33,443
Net carrying amounts of right-of-use assets included in property, plant and equipment	September 30, 2022	December 31, 2021
Facilities	\$ 81,637	\$ 89,343
Logistics and transportation equipment	33,472	33,443
Balance	\$ 115,109	\$ 122,786

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

14. Leases (continued)

Lease liabilities – Facilities	As at and for the nine months ended September 30, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 98,681	\$ 77,676
Add: additions	2,171	26,144
Add: additions through business combinations	2,006	8,475
Add: interest expense	2,752	3,700
Less: principal repayments	(12,462)	(13,756)
Less: interest payments	(2,752)	(3,700)
Foreign currency adjustments	420	142
Ending balance	\$ 90,816	\$ 98,681
Lease liabilities – Logistics and transportation equipment	As at and for the nine months ended September 30, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 28,282	\$ 27,270
Add: additions	7,464	7,431
Add: additions through business combinations	1,392	4,918
Add: interest expense	876	1,138
Less: principal repayments	(9,226)	(11,353)
Less: interest payments	(876)	(1,138)
Foreign currency adjustments	20	16
Ending balance	\$ 27,932	\$ 28,282
Cash lease principal payments	Nine months ended September 30, 2022	Year ended December 31, 2021
Repayments of lease principal	\$ (21,688)	\$ (25,109)
Total lease payments	\$ (21,688)	\$ (25,109)
Lease liabilities	September 30, 2022	December 31, 2021
Facilities	\$ (90,816)	\$ (98,681)
Logistics and transportation equipment	(27,932)	(28,282)
Balance	\$ (118,748)	\$ (126,963)
Lease liabilities included in consolidated balance sheets	September 30, 2022	December 31, 2021
Current	\$ (27,279)	\$ (26,446)
Non-current	(91,469)	(100,517)
Balance	\$ (118,748)	\$ (126,963)

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

14. Leases (continued)

Maturity analysis for lease liabilities – contractual undiscounted cash flows	September 30, 2022	December 31, 2021
Less than one year	\$ 32,420	\$ 30,839
One to 5 years	86,476	86,694
More than 5 years	15,818	23,360
Total undiscounted lease liabilities	\$ 134,714	\$ 140,893

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense for lease liabilities for the three and nine months ended September 30, 2022 was \$1,188 and \$3,628 respectively (September 30, 2021 – \$1,208 and \$3,611 respectively). Total cash outflow for leases for the three and nine months ended September 30, 2022 was \$8,542 and \$25,316 respectively (September 30, 2021 – \$7,454 and \$21,927 respectively).

Net investment lease	As at and for the nine months ended September 30, 2022	As at and for year ended December 31, 2021
Opening balance	\$ 784	\$ -
Add: additions	-	1,489
Add: interest received	10	29
Less: payments received	(540)	(705)
Less: interest income	(10)	(29)
Ending balance	\$ 244	\$ 784

In January 2021, the Company sub-leased a facility to a third party that had previously been classified as a right-of-use asset. The Company derecognized net book value of \$1,347 from right-of-use assets and established a net investment lease of \$1,489 resulting in a net gain of \$142 included in other income in connection with this facility. As at September 30, 2022 the current portion of \$244 (December 31, 2021 – \$723) in connection with this net investment lease is included in trade and other receivables. The long-term portion of \$nil (December 31, 2021 – \$61) is recorded in long-term deposits and other. The Company recognized \$10 of interest income for nine months ended September 30, 2022 (September 30, 2021 – \$24).

The table below sets out the current and long-term portions of the net investment lease:

Maturity analysis for net investment lease receivable – contractual undiscounted cash flows	September 30, 2022	December 31, 2021
Less than one year	\$ 245	\$ 734
One to 5 years	-	61
More than 5 years	-	-
Total undiscounted net investment lease receivable	\$ 245	\$ 795

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

15. Interest expense

Interest expense recognized in income and comprehensive income	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Leases	\$ 1,188	\$ 1,208	\$ 3,628	\$ 3,611
Credit facilities	489	362	1,294	1,043
Other	69	-	69	-
Total interest expense	\$ 1,746	\$ 1,570	\$ 4,991	\$ 4,654

Interest expense recognized in the consolidated statements of income and comprehensive income equates to total interest paid for the periods ended September 30, 2022 and 2021.

16. Commitments and contingencies

- The Company is, from time to time, involved in claims, legal proceedings and complaints arising in the normal course of business and provisions for such claims have been recorded where appropriate. The Company does not believe the final determination of these claims will have an adverse material effect on its consolidated financial statements.
- As at September 30, 2022, the Company had outstanding letters of guarantee in the amount of \$365 (December 31, 2021 – \$365).
- The Company has made commitments to lease fleet equipment, with the terms to begin upon delivery of the equipment in 2022. Commitments range from 72 to 84 months and total \$5,564 (December 31, 2021 – \$8,512).
- The Company has made commitments to purchase fleet equipment totalling approximately \$13,809 (December 31, 2021 – \$7,820).

17. Related parties

During the period, the Company entered into transactions with related parties that were incurred in the normal course of business. The Company's policy is to conduct all transactions and settle all balances with related parties on market terms and conditions. All outstanding balances with these related parties are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current period or prior period for bad or doubtful debts in respect of amounts owed by related parties.

The Company is indirectly controlled by Michael Andlauer, the Chief Executive Officer and CODM. Included in these consolidated financial statements are the following transactions and balances with companies related either directly or indirectly to Mr. Andlauer.

The Company recovers certain facilities lease costs from Andlauer Management Group Inc. ("AMG"). The Company also provides certain shared services (primarily accounting services) to AMG.

AHG acquired a 49% interest in Skelton USA on March 1, 2021 (note 4) which wholly owns Skelton Truck Lines, Inc. ("SKINC"). SKINC provides specialized 2-8°C transportation services to Skelton Canada Inc. in the United States, and Skelton Canada Inc. provides specialized 2-8°C transportation services to SKINC in Canada. On November 1, 2021, AHG acquired the remaining 51% of Skelton USA. Accordingly, transactions with SKINC have not been included in related party transactions in the tables below for the three and nine months ended September 30, 2022, but have been included for the period from March 1, 2021 to September 30, 2021.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

17. Related parties (continued)

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Revenue				
Transportation services				
1708998 Ontario Limited (Medical Courier Services)	\$ 41	\$ 111	\$ 132	\$ 282
Skelton Truck Lines, Inc.	-	383	-	1,086
Shared service recovery				
Andlauer Properties and Leasing Inc.	5	5	15	14
Andlauer Management Group Inc.	3	13	9	62
9143-5271 Quebec Inc.	8	8	24	23
1708998 Ontario Limited (Medical Courier Services)	3	4	9	10
Expenses				
Transportation services				
1708998 Ontario Limited (Medical Courier Services)	37	41	104	128
Med Express Ltd.	14	5	27	5
Skelton Truck Lines, Inc.	-	79	-	300
Contract labour services				
Ready Staffing Solutions Inc.	1,762	1,325	4,799	3,492
Equipment rent				
Andlauer Properties and Leasing Inc.	557	588	1,749	1,713
Facility rent				
Andlauer Properties and Leasing Inc.	358	443	1,340	1,328
9143-5271 Quebec Inc.	383	383	1,149	1,149
Maintenance services				
D.C. Racking and Maintenance Inc. and Logiserv Inc.	-	12	14	18
Travel services				
C-GHBS Inc.	-	53	72	53
Capital Expenditures				
Purchases of logistics and transportation equipment				
Logiserv Inc.	-	-	47	-

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

17. Related parties (continued)

	September 30, 2022	December 31, 2021
Trade receivables due from related parties		
Andlauer Properties and Leasing Inc.	\$ 13	\$ 74
Med Express Ltd.	-	2
1708998 Ontario Limited (Medical Courier Services)	31	32
	44	108
Due from related parties		
Andlauer Management Group Inc.	54	16
Former T.F. Boyle Transportation shareholders	-	92
	54	108
Total due from related parties	\$ 98	\$ 216
Trade payables due to related parties		
Ready Staffing Solutions Inc.	\$ 483	\$ 343
Andlauer Properties and Leasing Inc.	75	302
Logiserv Inc.	-	7
	558	652
Due to related parties		
Andlauer Properties and Leasing Inc.	123	254
Former Skelton Canada Inc. shareholders	-	1,032
	123	1,286
Total due to related parties	\$ 681	\$ 1,938

Key management personnel

The Company's key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include the Company's CEO, four named executive officers comprising key management and the Board of Directors.

Key management personnel compensation comprised the following:

	Three months ended September 30, 2022	Three months ended September 30, 2021	Nine months ended September 30, 2022	Nine months ended September 30, 2021
Key management compensation				
Salaries and benefits	\$ 876	\$ 837	\$ 2,622	\$ 2,473
Share-based payment arrangements	106	166	319	509
Director deferred share units	155	155	465	467
Total key management compensation	\$ 1,137	\$ 1,158	\$ 3,406	\$ 3,449

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

18. Capital management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital, as well as the level of dividends and distributions to ordinary shareholders.

The Board of Directors seeks to maintain a balance between the higher returns that might be possible with higher levels of borrowing and the advantages and security afforded by a sound capital position. The Company monitors capital using a net leverage ratio, calculated as net debt divided by the last twelve months' earnings before interest, taxes, depreciation and amortization ("EBITDA"). The Company seeks to keep its net leverage ratio below 3.0 in the ordinary course of business.

	September 30, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Total lease liabilities	118,748	126,963
Term facility	49,489	49,288
Less: cash and cash equivalents	(50,683)	(24,990)
Net debt	117,554	162,261
Last twelve months' net income	109,555	89,954
Last twelve months' interest income	(235)	(198)
Last twelve months' interest expense	6,556	6,219
Last twelve months' income tax expense	25,920	18,486
Last twelve months' depreciation and amortization	61,680	42,716
EBITDA	203,476	157,177
Net leverage ratio	0.58	1.03

19. COVID-19 pandemic

The extent to which the COVID-19 pandemic and its effect on the economy will impact the Company's business in the future remains uncertain and may lead to adverse changes in cash flows, working capital levels, debt balances, operating results and financial position in the future. The situation is dynamic and the ultimate duration and magnitude of the impact on the economy and the Company's business is not known at this time. The Company's pandemic management response team meets regularly as needed to review procedures, service levels, news, and Health Canada updates to address any challenges as they arise. At this time, management does not believe there is any immediate risk of significant disruption to the Company's services. In the event of a future significant disruption to service, management will work closely with the Company's clients, suppliers and regulatory authorities to prioritize the supply and delivery of essential medications and supplies.

The Government of Canada introduced the Canada Emergency Wage Subsidy ("CEWS") as part of its COVID-19 response. The program was effective from March 2020 to October 2021 and provided a wage subsidy for entities that experienced revenue declines over the comparable period in the prior year. During the three and nine months ended September 30, 2021, the Company recorded a \$270, and \$1,157 respectively, reduction to direct operating expenses in connection with the CEWS for its Nova Pack Ltd. subsidiary.